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ABSTRACT 
Emerging interest among consumers as to the health benefits of soy and a shifting 
preference toward more economical sources of protein has led to the increased global 
interest in soy protein. However, the main drawback to the expanded use of soy protein is 
its allergenicity, as soy is listed among the “Big 8” food allergens by the Food and Drug 
Administration (FDA). Therefore, in order to prevent a decrease in the momentum behind 
the usage of soy protein ingredients, different protein modification techniques must be 
explored in order to reduce the allergenicity of soy. Extensive enzymatic hydrolysis can 
reduce the allergenicity of a protein. However, this technique has negative consequences 
such as decreased protein functionality and bitter flavor.  In order to limit enzymatic 
hydrolysis, response surface methodology (RSM) can be used to determine the optimized 
combination of factors, such as time, temperature and enzyme to substrate ratio, that 
results in the maximum reduction in immunoreactivity of the modified protein, while 
maintaining quality. Enzymatic hydrolysis, however, when limited, may only reduce the 
immunoreactivity to a certain extent. Thus a second technique, such as Maillard-induced 
glycosylation may further reduce the allergenicity of the minimally hydrolyzed soy 
protein.  
The first objective was to determine optimal hydrolysis conditions for a maximum 
reduction of soy protein allergenicity using response surface methodology. The second 
objective was therefore to determine the effect of limited and controlled Maillard-induced 
glycosylation on the allergenicity of soy protein hydrolysate produced under optimized 
conditions from objective 1.  
A central composite design (CCD) was used to produce different soy protein 
hydrolysate (SPH) samples using Alcalase 2.4L with 3 independent variables; 
temperature (x1), time (x2), and enzyme to substrate ratio (E:S) (x3), with the degree of 
hydrolysis (DH) and the % reduction in immunoreactivity as the response variables. 
Western blots and ELISA were used to evaluate the immunoreactivity of the different 
hydroylsates using sera from different soy allergenic individuals. The design included 20 
experimental units with 6 center points to assess experimental variability, 8 factorial 
  iv 
points, and 8 alpha points to assess potential curvature in the data. The effects of the 
different independent variables on the responses were assessed by fitting the data to the 
appropriate model. Once a model was selected, 3D plots were generated. Once all of the 
responses were fit to the appropriate models, constraints were then added onto the levels 
of the variables that resulted in a DH greater than 8%. The predicted % reductions in 
immunoreactivity were then determined for each individual sera with the added 
constraints. Due to overlap in the predicted optimum response among the sera, one set of 
conditions was chosen to produce one optimized hydrolysate. Maillard-induced 
glycosylation of the optimized hydrolysate was conducted using conditions that were 
carefully selected to control the reaction. Several different measurements were done to 
assess the progression of the reaction, including Amadori compound formation, 
browning, lysine blockage, and fluorescence, all of which confirmed limited progression 
of the reaction. The immunoreactivity of SPH, partially glycosylated soy protein 
hydrolysate (PGSPH), and partially glycosylated soy protein (PGSP) was determined 
using ELISA and Western blots.  
Significant reductions in immunoreactivity (up to 58%) were observed for the 
different hydrolysates produced using RSM. Variability among sera was observed for the 
different hydrolysates, which was attributed to the resulting protein and protein/peptide 
profile upon hydrolysis. Different hydrolysis conditions may have resulted in the 
exposure or elimination of IgE binding regions (epitopes). Using RSM modeling, the 
optimized hydrolysis conditions were determined and the resulting SPH had a DH of 
7.8% and a % reduction in immunoreactivity ranging from 20-52%. When the produced 
SPH was subjected to controlled Maillard-induced glycosylation, a significantly (P ≤ 
0.05) higher % reduction in immunoreactivity (up to 83%) was observed when using 
serum that had the highest soy specific IgE (45.30 kU/L). Results from this work, for the 
first time, showed that two different protein modification techniques can be utilized in 
combination to substantially reduce the allergenicity of soy protein while maintaining 
quality. Therefore, limited enzymatic hydrolysis combined with controlled Maillard-
induced glycosylation has great potential for the development of hypoallergenic protein 
ingredients.  
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1. LITERATURE REVIEW 
1.1 Research and Objectives 
 
 
Interest in soy protein ingredients is expected to continue to increase globally as a 
result of their nutritional benefits, desirable functionality in various food applications, 
and consumer’s shift toward more plant-based economical protein sources. One of the 
biggest obstacles, however, to the expanded use of soy protein ingredients is their 
allergenicity. Currently, in the United States, food allergies affect 15 million people, 
equating to 4% of adults and 8% of children (Branum & Lukacs, 2008). Soy is among the 
“Big 8” food allergens declared by the Food and Drug Administration (FDA). The “Big 
8” food allergens, peanut, soy, egg, fish, shellfish, treenuts, wheat, and milk are 
responsible for 90% of allergic reactions (Food Allergy Research and Education, 2013). 
In the United States, 0.5% of the population has an allergy to soy (Sicherer et al., 2006), 
with strict avoidance of products containing soy as the only recommended treatment. 
To date, 33 different allergenic proteins in soy have been identified (FARRP, 2010). 
Ninety percent of people allergic to soy elicit allergic responses to only a few of the 
proteins including: Gly m Bd 30 K, Gly m Bd 28 K, Gly m Bd 60 K, and G1 and G2 
subunits from glycinin (Beardslee et al., 2002).  The known threshold of soy that will 
elicit an immune response is in the range of 0.0013-500 mg. Allergy symptoms 
traditionally include mild eczema, rhinitis, and inflammation. Although rare, reports of 
anaphylactic shock have occurred after the consumption of soy containing foods 
(Foucard et al., 1999). It is, therefore, crucial to develop techniques that can eliminate soy 
protein allergenicity so that the usage of such a nutritious and functional ingredient does 
not decrease overtime. 
Different techniques have been employed to develop hypoallergenic soy protein 
ingredients. Enzymatic hydrolysis has been found to significantly reduce the allergenicity 
of soy protein, but has had limited food applications due to the release of bitter peptides 
and loss of protein functionality as a result of high degrees of hydrolysis (Sun, 2011). 
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Maillard-induced glycosylation has also been explored for the development of 
hypoallergenic soy protein ingredients. Although a notable reduction in allergenicity has 
been reported, the conditions tested have led to nutritional quality loss due to the extent 
of lysine blockage, and adverse effects on overall quality  (Babiker et al., 1998; Usui et 
al., 2004). Genetic modification of soy has also been investigated. However, after 
modification, most of the functional characteristics of the protein were lost, which 
severely limited its suitability for food applications (Samoto et al., 1997).  
Limited hydrolysis along with controlled Maillard-induced glycosylation is 
hypothesized to have a synergistic effect on reducing the allergenicity of soy protein 
while maintaining nutritional value and quality. Maintaining a degree of hydrolysis 
(%DH) between 2-8% will avoid the release of bitter peptides and retain or enhance 
protein functionality (Alder-Nissens, 1986). Enzymatic conditions including time, 
temperature, enzyme to substrate ratio, along with the enzyme used, will affect the 
characteristics of the hydrolysate produced. Thus, in order to produce a hydrolysate with 
a degree of hydrolysis between 2-8% and with reduced allergenicity, enzymatic 
conditions must be optimized.  Similarly, Maillard-induced glycosylation conditions must 
be optimized to control the propagation of the Maillard reaction to the advanced stages 
and limit the extent of lysine blockage.  
Therefore, the objective of this research is to develop a hypoallergenic soy protein 
ingredient using a combination of enzymatic hydrolysis and Maillard-induced 
glycosylation. This work, for the first time, will provide information about the combined 
effect of limited enzymatic hydrolysis and controlled Maillard-induced glycosylation on 
the allergenicity of soy protein. The specific objectives for this work are: 
1) Determine optimal hydrolysis conditions for maximum reduction of soy protein 
allergenicity using response surface methodology.  
2) Determine the effect of limited and controlled Maillard-induced glycosylation on 
the allergenicity of soy protein hydrolysate produced under optimized conditions 
from objective 1.  
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1.2 Significance of Soy  
 
Soybeans are recognized throughout the world for their high protein content (40%) 
and oil content (20%). In the United States, $3.29 billion bushels of soybeans were 
produced trailing only corn in 2013 (United States Department of Agriculture-Foreign 
Agricultural Service, 2014). The estimated farm value of soy was $43 billion in 2013 
(United States Department of Agriculture-Foreign Agricultural Service, 2014). As a 
result of soy’s abundance, nutritional value, and low cost, it is one of the major crops 
found in the world’s food supply, with the United States exporting 1.7 billion bushels of 
soybeans last year, which amounted to a market value of $28 billion; a substantial 19% 
increase from the year prior (United Soybean Board, 2013; United States Department of 
Agriculture-Foreign Agricultural Service, 2014). 
The sales of soy containing foods was $300 million in 1992, and increased up to $5.2 
billion in 2011 (Soyfoods Association of North America, 2011). Increases in the sales of 
soy containing foods is attributed to the repositioning of soy containing foods in the 
market place, consumer preference shifting toward more plant based sources of protein, 
and an increased awareness among consumers of the health benefits of soy. In fact, the 
2010 Dietary Guidelines for Americans published by the Department of Health and 
Human Services and United States Department of Agriculture recommended soy protein 
as a quality protein source.  Not only are soy protein-based products good alternatives for 
vegetarians and lactose-intolerant individuals, but they also provide health benefits for 
the general public as well, due to their health benefits. 
 
1.3 Soy and Potential Health Benefits 
 
Soy consumption has been associated with several physiological benefits such as 
LDL cholesterol level reduction, weight management and satiety, and increased bone 
density. Many epidemiological and clinical studies have provided supporting evidence 
for the correlation of soy protein consumption with the aforementioned benefits. 
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Consumers have, therefore, become increasingly aware of the health benefits linked with 
the consumption of soy protein. In a recent survey, 47% of consumers specifically 
purchase products containing soy as compared to only 31% in 2010 (Soyfoods 
Association of North America, 2011). Market reports have found that 18% of consumers 
associate the phrase “good for you” with soy products as compared to only 14% in 2012 
(Soyfoods Association of North America, 2011). In fact, the relationship between soy and 
heart health is something that 12% of consumers are aware of (Soyfoods Association of 
North America, 2011). 
 
1.3.1 Cardiovascular Disease 
 
In the United States, cardiovascular disease (CVD) is the number one cause of death. 
The risk factors associated with CVD include elevated LDL cholesterol, obesity, 
diabetes, hypercholesterolemia, and hypertension (American Heart Association, 1999). 
The consumption of soy protein has been found to reduce an individual’s risk for 
cardiovascular disease. For example, the high percentage of the amino acid arginine in 
soy as opposed to other amino acids such as lysine and methionine is believed to reduce 
the secretion of insulin and glucagon preventing lipogenesis (Porter, 1995). The 
relationship between soy and LDL cholesterol reduction has been heavily studied.  
Notable reductions in LDL cholesterol levels have been observed when soy protein 
has replaced animal protein in the diet (Anderson et al., 1995; Oldewage-Theron et al., 
2013). This effect was more significant in individuals that were classified as 
hypercholesterolemic prior to switching to a soy-based diet. Reductions in LDL 
cholesterol were observed in individuals that were placed on a soy-based diet, regardless 
of their LDL cholesterol level prior to the consumption of soy (Anderson et al., 1995).  
Intakes of 25-50 g of soy protein each day have been found to reduce cholesterol levels 
by 8.9-17.4 mg/dL (Anderson et al., 1995). The reasoning behind these observed effects 
remains unclear, but it is hypothesized that soy protein increases the number of LDL 
receptors, allowing for an increased uptake of LDL particles into cells to replace secreted 
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bile acid, which in turn lowers cholesterol levels (Huff et al., 1984). Evidence about the 
correlation between soy and serum cholesterol levels has led to an FDA approved health 
claim in regard to soy protein and its prevention of heart disease “25 grams of soy protein 
a day, as part of a diet low in saturated fat and cholesterol, may reduce the risk of heart 
disease” (FDA, 1999).  
 
1.3.2 Weight Management and Satiety 
 
Increased consumption of protein as opposed to carbohydrates has been shown to 
increase satiety, which promotes weight loss as a result of a decrease in caloric intake 
(Paddon-Jones et al., 2008). There is considerable evidence that soy protein may further 
promote the feeling of satiety in comparison to other types of protein (Anderson et al., 
2004; Paddon-Jones et al., 2008). In animal models, the consumption of soy protein 
resulted in increased levels of thyroid hormones, which are involved in metabolism 
(Aoyama et al, 2007). Thyroid hormones affect lipid metabolism by promoting the usage 
of lipid based substrates within the body and enhancing the activity of lipoprotein lipase 
(Pucci et al., 2000). It is also hypothesized that soy protein may have an effect on body 
weight due to its effect on sterol regulatory element binding proteins (SREBP). The 
regulation of genes that are involved in fatty acid and cholesterol synthesis are stimulated 
by SREBP. Soy protein has been found to down regulate the expression of SREBP 
(Velasquez et al., 2007).  
 
1.3.3 Bone density  
 
Women are at high risk for a decrease in bone density during menopause mainly due 
to decreases in estrogen levels within the body. Positive correlations between soy and its 
prevention of bone desorption have been found. Women who consumed soy had 
decreased levels of urinary calcium excretion (Armandi et al., 2003).  The decreased 
levels of sulfur containing amino acids in soy are suspected to enhance the ability of soy 
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to aid in the retention of calcium in the bones (Cai et al., 2001; Kaneko et al., 1990; 
Wang et al., 1998). When soy protein is consumed along with calcium, insulin like 
growth factor 1 (IGF-1) has been found to increase by 69% (Armandi et al., 2003). 
Increased presence of growth factors such as IGF-1 can positively influence the rate of 
bone formation.  
A growing number of consumers have reported increases in their consumption of soy 
based foods not only due to the preference of switching to plant-based protein, but also 
due to the increasing awareness among consumers about the health benefits associated 
with the consumption of soy. Consequently, the utilization of soy protein ingredients in 
several food products is expanding. The anticipated growth rate of soy protein ingredients 
is around 6.5% per year, surpassing the anticipated growth rate of wheat (Frost et al., 
2012). The largest market shares for soy protein ingredients includes (arranged from 
smallest to largest): meat alternatives (10%), non-dairy beverages (14.7%), baby food 
(18.4%), and energy bars (20.2%) (Mintel Group, 2011).  
 
1.4 Soy Protein Ingredients and Their Application in Foods  
 
1.4.1 Soy Protein Ingredients  
 
Soy protein ingredients that are commonly used in the food industry include soy 
flour, soy protein concentrate (SPC), soy protein isolate (SPI), and soy protein 
hydrolysate (SPH). Soy flour, contains roughly 40-50% protein, depending on the type of 
flour (Rhee, 1994). Soy flour is produced by grinding and dehulling soy flakes. Five 
different forms of soy flour are available on the market including full fat soy flour, high 
enzyme flour, defatted soy flour, soy grits, and refatted flour. Full fat soy flour, the least 
processed, is approximately 40% protein and is primarily used for the production of 
soymilk (Rhee, 1994). High enzyme soy flour, on the other hand, contains roughly 52-
54% protein and offers advantages to the baking industry as it can aid in dough mixing 
tolerance and the flour bleaching process (Rhee, 1994).  
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Soy flour is also the starting material for the production of soy protein concentrates 
and isolates, but must first be defatted using hexane. Soy protein concentrate (SPC) 
contains at least 70% protein and is produced as a result of the addition of acid, aqueous 
ethanol extraction, or heat treatment followed by water extraction in order to remove 
water soluble components of dehulled and defatted soy flour (Rhee, 1994). This soy-
based ingredient contains 5-6% fiber.  Soy protein isolate (SPI), the most refined, 
contains at least 90% protein. Isoelectric protein precipitation is often used for the 
production of SPI. Defatted soy flour is first suspended in an alkaline solution to remove 
any insoluble residue, mainly starch and fiber. This step is then followed by 
centrifugation. The supernatant is then taken and the pH is adjusted to the isoelectric 
point of soy protein, which is 4.5, in order to precipitate the protein and separate it from 
the soluble sugars and oligosaccharides. The protein is then left at this pH and subjected 
to spray drying. The isolate that is produced from this process is best suitable for use in 
infant formulas and other applications for nutritional enhancement (Rhee, 1994). In other 
cases, the precipitated protein is brought back to a neutral pH prior to drying, when the 
product is intended to be used for its unique protein functionality. 
Soy protein hydrolysate (SPH) is also commercially available for food applications. 
This type of ingredient is traditionally prepared from SPI that has been subjected to 
enzymatic hydrolysis (Chiang et al., 1999). Most often SPH is used as a nutritional 
ingredient and more recently in the development of hypoallergenic infant formulas (Sun, 
2011). Soy protein hydrolysate based infant formulas are used for babies that have an 
allergy to milk proteins or are lactose intolerant. Recently, SPH is being used in medical 
enteral formulas as a replacement for animal protein (Clemente, 2001). Soy protein 
hydroylsate often has improved functionality compared to their intact counterpart and can 
be used as a source of bioactive peptides. Bioactive peptides are defined as protein 
sequences that exert a positive effect on different systems of the body such as 
cardiovascular, immune, digestive, and nervous systems (Dairy Science-Food 
Technology, 2013). Bioactive peptides are typically 2-9 amino acids long (Wang et al., 
2005), which are biologically active only upon the release from the parent protein 
sequence. Release of bioactive peptides is achieved either in vivo through the action of 
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digestive enzymes or in vitro through controlled enzymatic hydrolysis as in the 
production of SPH (Korhonen et al., 2006). 
 
1.4.2 Food Applications of Soy Protein Ingredients 
 
 Soy protein is suitable for a wide range of applications as a result of its unique 
functional properties such as emulsification, water and fat adsorption, and gelation 
properties (Usami, 1997). The functional attributes of soy protein ingredients are very 
important to the meat, bakery, and dairy analog industries. Brine solutions for different 
meat products contain either SPI or SPC to aid in the prevention of water and fat loss 
during cooking (Rhee, 1994).  The use of SPI or SPC in the formulation of bologna and 
frankfurters prevents moisture and fat loss in the finished product. The emulsification 
property of soy ingredients is useful for batter development in various baked products 
such as  cakes, crackers, pastries, and pancakes (Rhee, 1994). Fortification of breakfast 
cereals and pasta products with SPI is done to increase the overall protein content of the 
product (Rhee, 1994). Tofu and dairy analog products depend heavily on the gelation 
property of SPI to provide structural integrity that makes the final products similar to 
their dairy counterparts (Gaonkar et al., 2006). Most commonly, SPI is used in infant 
formulas for babies with a milk allergy. This dates all the way back to the 1900’s. 
Roughly, 25% of American babies are fed soy protein based infant formula (Agostoni, 
2006). 
1.5 Soy Protein Components 
 
Soy proteins are characterized based on their solubility in different systems. 
Albumins, for example, are soluble in water while globulins are soluble in a salt solution 
that is prepared at a neutral pH (Lampart-Szczapa, 2001). Around 80-90% of the protein 
found in soy is classified as globulin storage proteins, while the remaining 10-20% are 
characterized as albumins (Lampart-Szczapa, 2001). 
Four different fractions with varying Svedberg coefficients (rate of sedimentation) are 
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found in soy protein: 2S, 7S, 11S, 15S. The 7S and 11S components are the most 
abundant protein components accounting for 70% of the total protein, with the proportion 
of each being dependent on the cultivar and variety of soybean (Saio et al., 1977). 
The 2S fraction consists of several enzymes and proteins of several different 
molecular weights. For example, the Bowman-Birk inhibitor (7.8 kDa) and the Kunitz 
trypsin inhibitor (21.5 kDa) are among the constituents of the 2S fraction. Both proteins 
inhibit the activity of the enzyme trypsin, which is required for the in vivo digestion of 
proteins. These inhibitors are inactivated during heat processing.  
β-conglycinin (150-200 kDa), lipoxygenase (102 kDa), lectins (120 kDa), basic 7S 
globulin (168 kDa), and γ-conglycinin (170 kDa) are all found in the 7S fraction 
(Lampart-Szczapa, 2001). Lipoxgenase plays a role in oxidative reactions that have 
implications on overall taste (Lampart-Szczapa, 2001). The enzyme lipoxgenase can 
lead to the oxidation of fatty acids, primarily polyunsaturated fatty acids, forming 
hydroperoxides that are broken down to cis-n-hexnal which leads to a beany flavor in 
soy (Hui et al., 2004). Lectins, on the other hand, are classified as glycoproteins that 
have anti-nutritional properties (Lampart-Szczapa, 2001). Agglutination, or the joining 
together of human red blood cells, is a property that some lectins found in soy possess 
(Lampart-Szczapa, 2001). The process of agglutination can lead to the formation of 
blood clots.  
The β-conglycinin component, which represents 30-50% of the total protein in soy 
has been studied in great detail (Lampart-Szczapa, 2001). β-conglycinin, a glycoprotein 
that contains 4-5% carbohydrate, is a trimer made up of a combination of the following 
subunits: β (52 kDa), α (68 kDa), α’ (72 kDa). Seven different combinations of the 
subunits have found to exist in soy: ααα, ααα’, ααβ, αα’β, αββ, α’ββ, and βββ. The 
subunits are commonly held together by hydrophobic interactions. Sequence homology 
is found among the three subunits, however differences are seen in the relative amounts 
of cysteine, methionine, and tryptophan, leading to a better nutritional profile for α’, 
followed by α, and then β. The association and dissociation of β-conglycinin subunits 
depends on both the pH and ionic strength of the system. When the pH is neutral and the 
ionic strength is greater than 0.5 or when the pH is below 4.8, β-conglycinin will exist as 
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a trimer. A hexamer can be formed, with an average sedimentation coefficient of 10S, 
when the ionic strength is less than 0.2 and the pH is between 4.8-11.  
The 11s fraction, also commonly referred to as glycinin, has a molecular weight range 
of 300-380 kDa, and is composed of 6 different monomers. Five different monomers 
have been identified: G1 (A1aB2), G2 (A1bB1b), G3 (A2B1a), G4 (A3B4), 
G5(A5A4B3). The ratio of the monomers is dependent on the soybean variety.  A 
monomer is composed of acidic (~35 kDa) and basic (~20 kDa) subunits that are held 
together by disulfide bonds. The monomers interact by hydrophobic interactions to form 
a trimer. Trimers can further be arranged on top of each other to form a hexamer by 
electrostatic interactions and hydrogen bonding. 
The functionality of soy protein is mainly attributed to glycinin and β-conglycinin, 
with glycinin being a better gelation agent and β-conglycinin a better emulsifying agent. 
The presence of sulfhydryl groups in glycinin aids in the formation of strong gels and the 
size and surface characteristics of β-conglycinin aid in the formation of stable emulsions. 
Therefore, the ratio of glycinin to β-conglycinin is a key factor that influences the final 
application. Having unique functionality, glycinin and β-conglycinin contribute to the 
overall structure and acceptability of many foods. However, both glycinin and β-
conglycinin proteins are among the main allergens in soy.  
 
1.6 Soy Protein as a Food Allergen 
 
A food allergy is traditionally defined as an IgE mediated immune response that is 
due to an individual’s interaction by inhalation, ingestion or skin contact with an 
offending molecule, which is commonly a protein (L’Hocine and Boye, 2007). Soy is 
among the “big eight” allergens declared by the Food and Drug Administration (FDA). 
The “big eight” allergens, which are responsible for 90% of allergic reactions include: 
peanut, soy, egg, fish, shellfish, tree nuts, wheat, and milk. The number of people with an 
allergy to soy in the United States is roughly 0.5% of the population (Sampson, 2004; 
Sicherer & Sampson, 2006; Stephan et al., 2004). The threshold for the amount of soy 
that can lead to an immune response varies between individuals, but current reports have 
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found that as little as 0.0013 mg - 500 mg may trigger a response (L’Hocine and Boye, 
2007). 
 
1.6.1 Allergenic Response  
 
An allergic reaction can be broken down into two different phases: sensitization and 
an allergic reaction (Abul et al., 2011).  The sensitization phase occurs during the initial 
exposure to an antigen. Dendritic cells are an example an antigen-presenting cell (APC) 
that recognizes protein sequences on the antigen. This type of cell will process and 
present the antigen on the cell surface along with the major histocompatibility complex 
(MHC) class II molecule needed for recognition by naive CD4+ T cells. After the antigen 
has been presented, the naive CD4+ T cells will then differentiate into TH2 T-helper 
cells, leading to the secretion of cytokines, mainly interleukin 4 and 13, which in turn 
leads to the secretion of IgE from B cells. Circulating IgE will then bind to the high 
affinity Fcε receptors that are present on the surface of mast cells. During the period of 
sensitization, many IgE molecules specific for the antigen of interest will bind to a mast 
cell, making the mast cell more sensitive to IgE produced in response to a second 
encounter with the antigen. After the sensitization period, the subsequent exposure to an 
antigen will result in an allergic response.  
IgE cells found on mast cells are sensitive to the antigen after the sensitization phase. 
When the offending antigen is recognized by IgE, as demonstrated in Figure 1.1, the IgE 
and Fcε receptor found on the mast cell become cross-linked leading to the secretion of 
different biochemicals including prostaglandins, histamine, and leukotrienes. Different 
responses are seen throughout the body (Figure 1.1) and may include dilation of blood 
vessels, prolonged muscle contraction, rhinitis, inflammation, and hives. Although rare, 
reports of anaphylactic shock have occurred after the ingestion of soy.  
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Figure 1.1. Overview of an allergic reaction  
 
During the allergic response, IgE attached to mast cells can bind to specific regions 
on the antigen, referred to as epitopes. The epitopes can either be linear, which is simply 
a linear sequence of amino acids, or conformational (discontinuous), which is formed due 
to the secondary or tertiary folding of the protein (Figure 1.2). Limited work has been 
carried out to determine and identify different conformational and linear epitopes in soy.  
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Figure 1.2. Linear (sequential) and conformational (discontinuous) epitopes involve in an 
immune response. 
 
1.6.2 Allergenic subunits  
 
To date researchers have identified thirty-three different allergenic proteins in soy 
(FARRP, 2010). Only a few of the thirty-three allergenic proteins in soy are linked to 
adverse responses (L’Hocine and Boye 2007). The molecular weight range of known 
allergens in soy ranges from 7-71 kDa (L’Hocine and Boye 2007). No link yet has been 
found between the recognition of a specific epitope and symptoms that an individual may 
experience.  
The P34 subunit, which is considered to be the immunodominant allergen in soy, is a 
glycoprotein that is believed to play an important role in the folding of soy protein due to 
the presence of disulfide linkages (Babiker et al., 2000; Kalinski et al., 1990; Ogawa et 
al., 1993). Approximately 65% of people with an allergy to soy are sensitive to P34 
(Helm et al., 1998). Sixteen different linear epitopes have been identified on this protein, 
five of which are characterized as the immunodominant epitopes (Helm et al., 1998). 
Following extensive amino acid sequence analysis has found that the sugar moiety, which 
is a fucosyl group, that is linked to asparagine was identified as an additional epitope 
Conformational epitope
Linear epitope
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(Babiker et al., 2000; Kalinski et al., 1990; Ogawa et al., 1993). 
Reports on the allergenicity of β-conglycinin subunits have been controversial. 
Krishnan et al. (2009) concluded that all three subunits (α, α’, and β) were allergenic, 
based on Western blots produced using sera from seven different allergenic donors. Three 
of the patients had IgE binding to protein bands corresponding to the different β-
conglycinin subunits: α’, α, and β respectively. However, Ogawa et al. (1995) has found 
that the α’ subunit is not allergenic. Discrepancies as to whether or not all three subunits 
are allergenic is mostly attributed to variation among the sera obtained from patients of 
different age groups and sensitization histories (L’Hocine and Boye,  2007; Ogawa et al., 
1993).  
Similarly, contradictory results have been reported regarding the allergenicity of the 
glycinin subunits. Some researchers have found that soy specific IgE binds to the acidic 
subunits with minimal if any binding to the basic subunits (Pedersen et al., 1989).  
However, other researchers have found both the acidic and basic subunits of glycinin can 
bind to IgE (Helm et al., 2000). Using epitope mapping, eleven linear epitopes were 
identified on the G2 subunit, with four of them considered as immunodominant (Figure 
1.3) (Helm et al., 2000). 
Allergic reactions to soy have been reported for individuals that work in soybean 
mills. It was assumed that workers came into contact with soybean allergens by 
inhalation. Testing conducted on the workers suggested that they had IgE antibodies that 
bound to the Kunitz trypsin inhibitor protein that has a molecular weight of ~20 kDa 
molecular weight marker (Figure 1.3) (Duke, 1934; Moroz et al., 1980). Other soybean 
aeroallergens have been identified, namely, Gly m 1.0101, Gly m 1.0102, and Gly m 2. 
Researchers from Barcelona were able to identify these aeroallergens after several 
incidences of asthma occurred among large populations in Spain (Codina et al., 1997).  
The Gly m 3 or soybean profilin was capable of binding IgE (Amnuaycheewa et al., 
2010) using a PCR cloning method to generate recombinant soybean profilin. Epitope 
mapping confirmed that IgE could bind to the recombinant protein as long as the protein 
was in its native form, suggesting that the epitopes on this protein are conformational 
(Rihs et al., 1999).  
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Figure 1.3. Known allergenic subunits in soy protein identified by molecular weight in 
kDa. 
Crossreactivity between legume proteins such as soy and peanut has been reported. 
Epitopes are frequently around ten to fifteen amino acids long. Due to a relatively high % 
homology (Table 1.1) between legume proteins, similar epitopes can be found in both 
peanut and soy protein (Wilson et al., 2005). The number of people with an allergy to soy 
can be higher than current estimates, yet appears lower as individuals may be 
misdiagnosed as having a peanut allergy instead (Foucard, 1999). The P34 subunit in soy, 
which 65% of individuals with an allergy to soy are allergic to, shares 70% homology 
with the Ara h 1 subunit found in peanut protein (Wilson et al., 2005). Clinical examples 
of crossreactivity have also been reported. For example, in Sweden, 3 children had 
anaphylactic reactions after consuming meat products that contained soy protein. All of 
the patients had a diagnosed allergy to peanuts, but not to soy (Wilson et al., 2005). The 
crossreactivity between soy and peanut protein has been explored as a means to reduce 
the likelihood of an allergic reaction. Low doses of soy protein have been used to help 
minimize the immune response to peanut allergens in peanut sensitive mice (Pons et al., 
2004). 
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 Acidic chains (A1, A2, A3, A4): 
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Table 1.1. Crossreactivity of soy with other allergens
* 
 
*
Ziang et al. 2000; Wilson et al., 2005 
 
 
A 73% reduction in the immunoreactivity of sera from peanut sensitive individuals 
with peanut antigen was found when affinity chromatography was used to remove soy 
specific IgE (Eigenmann et al., 1996). This observation confirms that extensive 
crossreactivity is found among legume proteins, specifically peanut and soy, which 
contributes to the belief that the incidence of soy allergies in the United States is much 
higher than reported. Researchers have currently been investigating more definitive 
immunological tests to confirm which particular antigen an individual is allergic to and 
whether or not crossreactivity plays a role in the allergenic response.  
Work has also been done in order to find allergens that are unique to only soy and do 
not have crossreactivity with other known allergens. A soy specific IgE reacted with a 
protein band around 20-22 kDa in western blots when using sera from patients that only 
have an allergy to soy (Herian et al., 1990). Several other researchers have confirmed this 
trend and have determined that the protein band found around 20-22 kDa is most likely 
the basic chain from glycinin (Helm et al., 2000). The determination of unique subunits 
that do not have crossreactivity with other subunits from other proteins will allow for a 
more definitive conclusion as to whether an individual has an allergy specifically to soy 
and is not exhibiting symptoms of an allergic reaction due to crossreactivity with another 
allergen. 
The only physician recommendation for individuals with an allergy to soy is strict 
	Soy Protein Molecular 
Weight 
(kDa) 
Crossreactivity 
G1, acidic from Glycinin 40.0 Ara h 3 - peanut 
G2, acidic chain from Glycinin 40.0 Ara h 3 - peanut 
P34 34.0 Ara h 1 - peanut 
Profilin 14.0 Bet v 2 - birchwood 
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avoidance of foods containing soy. This can be difficult as soy and peanuts are found in 
over 6,000 different products (Helm et al., 2002). Most allergic reactions to soy are 
considered mild and include hives, inflammation, rhinitis, and blood vessel dilation.  
Severe reactions are rare when compared with other allergens, such as peanuts and 
treenuts, but reports of anaphylactic shock after consuming bread, pizza, and sausage that 
contained soy protein has occurred (Foucard et al., 1999). The increased exposure to soy 
protein may result in increased incidences of soy protein allergy. Therefore, the 
increasing market demand for soy protein based foods should be complemented with 
efforts to improve the quality and enhance the safety of soy protein for all consumers.  
Thus, it is imperative to investigate different techniques to reduce the allergenicity of soy 
in order to further the usage of soy protein as a functional ingredient with multiple 
physiological benefits. 
 
1.7 Methods to Reduce the Allergenicity of Soy Protein 
 
Several different protein modification techniques have been tested in order to reduce 
the allergenicity of soy protein including, thermal treatment, genetic modification, 
enzymatic hydrolysis, and Maillard-induced glycosylation. Linear epitopes can be 
targeted by techniques such as enzymatic hydrolysis while conformational epitopes can 
be modified by thermal treatment, enzymatic hydrolysis, and chemical modification. In 
order for an ingredient to be declared as hypoallergenic, according to the American 
Academy of Pediatrics and the European Society for Pediatric Gastroenterology and 
Nutrition, it must not lead to an allergic reaction in 90% of patients who have a 
diagnosed allergy with a 95% limit of confidence (L’Hocine and Boye, 2007). 
 
1.7.1 Thermal treatment  
 
Thermal treatment has been utilized as a method to develop hypoallergenic soy 
protein ingredients. Soy extract heated at 80°C, 100°C, and 120°C for 30 minutes 
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demonstrated a 40-75% reduction in immunoreactivity when using sera from soy 
allergenic donors for radioallergosorbent (RAST) inhibition testing (Shibasaki et al., 
1980). Heating at 80°C, however, lead to an increase in immunoreactivity for the 2S 
fraction. In a RAST inhibition test, antigen specific IgE will either bind to insoluble 
material, which contains the antigen of interest, or remain in the sera (Grammer et al., 
2012). A radiolabeled antibody is added to detect any IgE antigen interaction. A decrease 
in allergen specific IgE binding indicates a greater reduction in immunoreactivity. In 
another study conducted by Müller et al. (1998) heating soy to 100°C for 2 hours resulted 
in an 89% reduction in immunoreactivity as confirmed by RAST inhibition testing. 
However, the research conducted by Burks et al. (1992) showed no reduction in IgE 
binding in a RAST inhibition test when soy was heated at 100°C for 60 minutes.  
Although, significant reductions in immunoreactivity have been reported after 
thermal treatment, this technique is highly variable as demonstrated by contradictory 
EAST inhibition tests. Inconsistencies among the reports on the effect of thermal 
treatment on soy protein allergenicity can be attributed to several different factors 
including pH and ionic strength of the surrounding environment, temperature, heating 
time, and specific characteristics of the protein (Davis et al., 1998). For example, the 
glycinin subunit in soy at a pH of 7.6 will be found in hexameric complexes, while it will 
exist in trimeric complexes at a pH of 3.8 (Lakemond et al., 2000). Changes to the 
secondary and tertiary structure have been reported when glycinin is found in the 
hexameric or trimeric complex, which may expose certain epitopes as a result of 
conformational changes (Codina et al., 1998; Lakemond et al., 2000). Ionic strength can 
also influence the arrangement of glycinin. When the pH is at 7.6 and the ionic strength is 
changed from 0.5-0.03, more of the basic subunits are found on the exterior of the protein 
(Lakemond et al., 2000). The secondary structure of a protein is typically affected by 
heating at temperatures of 55-70°C, while disulfide bonds are broken between 70-80°C 
(Poms et al., 2004).  The formation of new intra and intermolecular interactions occurs at 
80-90°C along with disulfide bond rearrangement, while protein aggregation occurs from 
90-100°C (Poms et al., 2004). Thermal treatment, therefore, may expose epitopes that are 
found within the interior of the protein or may lead to the formation of new epitopes that 
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can bind IgE (L’Hocine and Boye, 2007).  Additionally, heat-induced changes caused by 
thermal treatment can promote protein aggregation leading to negative consequences on 
the functionality, thus limiting the use of soy protein ingredients modified by thermal 
treatment in food applications (Sorgentini et al., 1995). 
 
1.7.2 Genetic Modification  
 
Genetic modification is another technique employed in order to aid in the 
development of hypoallergenic soy protein ingredients. Genetic engineering has been 
carried out to develop soy protein that is lacking Gly m Bd 28K and the α and α’ subunits 
of β-conglycinin (Samoto et al., 1997; Takahashi et al., 1994). However, the genetically 
engineered protein lost its gel forming ability, which may limit the usage of this 
ingredient in food applications as a result of the decreased functionality (Ogawa et al., 
2000). Soybeans have also been developed that lack both the glycinin and β-conglycinin 
subunits, which are the two main storage proteins that contribute to the functional 
properties of soy protein (Takahashi et al., 2003). No functionality testing has been 
conducted on the genetically modified ingredients lacking the major storage proteins, β-
conglycinin and glycinin. It is expected that the functionality of the ingredient would be 
significantly reduced. Researchers have found that the genetically engineered seeds that 
do not contain the β-conglycinin and glycinin fractions had elevated free amino acid 
content and an increased amount of other protein fractions, especially the P34, which is 
problematic as this protein is the immunodominant allergen in soy (Takahashi et al., 
2003). Additionally, consumer acceptance of genetically modified crops is a huge 
limitation for promoting their usage in food products (Riascos et al., 2010).  
 
1.7.3 Enzymatic hydrolysis  
 
Considerable reductions in soy protein allergenicity have been observed upon 
enzymatic hydrolysis. The extent of reduction in allergenicity is dependent on the 
incubation conditions and the enzyme utilized. There is a wide range of enzymes with 
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varying specificities that have been used to reduce the allergenicity of soy protein.  
Bacillus subtilis derived enzymes have been shown to be effective in hydrolyzing the 
P34 subunit, which 65% of individuals with a soy allergy are allergic to. When a western 
blot was done using a monoclonal antibody with specific reactivity to the P34 subunit, 
reactivity was no longer detected in the modified protein (Yamanishi et al., 1997). 
Reduction in the immunoreactivity of β-conglycinin using Bacillus subtilis has also been 
found (Tsumura et al., 1999). The reactivity of β-conglycinin, as determined by 
monoclonal IgE, was no longer detected following a western blot.  
The use of pepsin and chymotrypsin sequentially has also been investigated to reduce 
the allergenicity of soy protein (Lee et al., 2007). The immunoreactivity was assessed 
using an ELISA and sera from six allergenic donors. Hydrolysis using pepsin alone more 
effectively reduced the allergenicity of soy protein as compared to sequential pepsin and 
chymotrypsin digestion. Hydrolysis of the acidic subunits of glycinin was achieved with 
the hydrolysis by pepsin, while the basic subunit resisted enzymatic degradation 
regardless of the enzyme used (Lee et al., 2007). The resistance of the basic subunit to 
enzymatic degradation was related to its high relative hydrophobicity and overall 
compacted structure (Lee et al., 2007).  
Enzymatic hydrolysis can expose epitopes that are found in the interior hydrophobic 
domain of the protein or that are unaccessible in the native structure of the protein, 
especially linear epitopes that can bind IgE (L’Hocine et al., 2007). The extent of 
hydrolysis will influence the residual allergenicity of the final product. Most often 
immunological testing has only been conducted using monoclonal antibodies for a 
specific subunit. Although the reactivity of one subunit could be substantially reduced, 
other subunits may still be allergenic. A DH of 40% was found to be sufficient to 
effectively reduce the immunoreactivity of the P34 subunit (Tsumura et al., 1999).   
However, no testing was done to assess the immunoreactivity of glycinin and β-
conglycinin, which are found in the greatest abundance in soy and have the greatest 
impact on protein functionality (Tsumura et al., 1999). 
Due to the high DH achieved with enzymatic hydrolysis to reduce the allergenicity 
(13-40%), the functionality of soy protein, primarily protein solubility, gelation, and 
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emulsifying properties are negatively affected. Enzyme treatment to achieve a DH of 
only 14% altered the solubility of soy protein at different pH’s due to the increased 
exposure of hydrophobic residues that promote hydrophobic interactions particularly at a 
pH of 6 and less than 3.5 (Tsumura et al., 2005). Enzymatic modification to β-
conglycinin at a DH of 14% negatively affected its emulsification property at a neutral 
pH (Tsumura et al., 2005). Limited functionality testing has been conducted on 
hydrolysates with a DH of 40% except for gelation, which was found to be unaffected 
due to the selective hydrolysis of β-conglycinin, while glycinin remained intact (Tsumura 
et al., 1999). Enzymatic hydrolysis with chymotrypsin at 37°C for 18 hours resulted in no 
significant change in gelation relative to the unmodified soy protein (Babiker, 2000). 
Hydrolysis conditions and the enzyme utilized greatly influence the gelation ability of 
soy as a result of the generation of repulsive groups, number of free amino groups, and 
overall extent of protein denaturation (Kitabatake et al., 1989; Sakamoto et al., 1994; 
Schmidt, 1981). Most beneficial changes in soy protein functionality are achieved at low 
DH (often 2-8%) that does not exceed 10% (Alder-Nissen, 1984; Alder-Nissens, 1986). 
Soy is used in foods for its water and fat absorption, emulsification, and gelation 
properties, which can all be adversely affected as the DH increases. 
The production of bitter peptides is one of the major challenges of protein 
hydrolysates. Low molecular weight peptides that are hydrophobic are responsible for the 
perception of bitterness in hydrolyzed products (Sun, 2011). Bitterness is not normally 
detected in unmodified soy as the hydrophobic residues are orientated toward the interior 
and are unaccessable to the taste buds (Alder-Nissen, 1984). The production of bitter 
peptides increases as the DH increases with a noticeable bitterness perception at a DH 
>8% (Achouri et al., 1999; Aehle, 2007). However, peptides may still retain secondary 
structure at low DH and thus have the ability to interact by hydrophobic interactions, thus 
preventing the accessibility of the hydrophobic interior by the taste buds (Alder-Nissens 
et al., 1979). As the DH increases, the presence of hydrophobic amino acids on the 
terminal ends of the peptides, primarily isoleucine, tyrosine, tryptophan, and 
phenylalanine, increases.  No sensory data has been reported for hydrolysates with a DH 
of 40% and eliminated immunoreactivity of the P34 subunit. 
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1.7.4 Maillard-Induced Glycosylation  
 
Maillard-induced glycosylation is another protein modification technique that has 
been employed to develop hypoallergenic ingredients (L’Hocine and Boye, 2007). The 
Maillard reaction involves three main stages, initial, intermediate, and advanced. The 
initial stage is characterized by the condensation reaction involving the reducing end of a 
carbohydrate and an amine group of a protein. Most often, the amine group is from the 
amino acid lysine. The result of the condensation reaction is the formation of a Schiff 
base that can then rearrange to form the irreversible Amadori compound, which is often 
used as an indicator of glycosylation. In the intermediate stage, the Amadori compound is 
degraded by taking part in many reactions involving enolization, oxidation, dehydration, 
or cyclization. The advanced stage is characterized by the formation of melanoidins, 
which are insoluble and colored. Propagation of the reaction to advanced stages will 
result in excessive melanoidin formation, nutritional quality loss due to the extent of 
lysine blockage, and protein polymerization resulting in reduced digestibility. The 
advanced stage is also associated with the formation of carcinogens and mutagenic 
compounds. A modified protein with a high degree of lysine blockage would no longer 
meet the standards to be classified as a complete source of protein due to the 
inaccessibility of lysine.  
Several factors influence the propagation of the Maillard reaction including 
temperature, water activity (aw), pH, the carbohydrate used and incubation/storage time. 
The reaction can be difficult to control. Loss of protein quality is one of the major 
consequences associated with the Maillard-reaction (Martins et al., 2001). The extent of 
lysine blockage depends on the carbohydrate used. The use of polysaccharides may 
shield some lysine residues and prevent propagation to more advanced stages in 
comparison to the use of a simple sugar (Babiker et al., 1998). Additionally, the rate of 
the reaction is much slower with a polysaccharide as compared to a simple sugar. Time 
and temperature can also influence lysine blockage, with high temperatures and longer 
incubation times promoting more protein sugar interaction (Martins et al., 2001). A water 
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activity (aw) range of 0.5-0.8 promotes fast propagation of the Maillard reaction (Ames, 
1990). Excessive browning is often seen at higher temperatures and longer incubation 
times (Martins et al., 2001).   
The potential of the Maillard-reaction to reduce the allergenicity of a protein is 
complex. Some researchers have found that if the reaction is allowed to progress to the 
advanced stage, epitopes that can bind IgE may be formed as a result of the crosslinking 
of protein (Maleki et al., 2000; Pastorello et al., 2002), thus making the protein more 
allergenic. Other researchers have used different sugars to induce Maillard glycosylation 
in order to reduce the allergenicity of soy protein.  
Galactomannan, a polysaccharide with a backbone made from repeating mannose 
units and galactose side chains, has been used to produce a glycosylated soy protein 
(Babiker et al., 1998). The immunoreactivity of the P34 subunit as tested by western blots 
was eliminated completely upon glycosylation with galactomannan for an incubation 
time of up to 14 days at 0.79 aw and 60°C. However, no information about the extent of 
lysine blockage was reported. Additionally, the extent of propagation to the advanced 
stages was also not addressed. 
Other researchers have used chitosan, a polysaccharide composed of glucosamine and 
acetylglucsamine for the Maillard-induced glycosylation of soy protein (Usui et al., 
2004). Testing once again focused on the P34 subunit, the immunoreactivity of which 
was eliminated upon glycosylation for 2 weeks at 60°C and 0.65 aw. Individuals with an 
allergy to soy may be allergic to other proteins found in soy other than the P34 subunit.  
Furthermore, the authors did not provide information on the extent of lysine blockage or 
the extent of propagation to the advanced stages of the Maillard-reaction.  
Fructooligosaccharides have also been used to reduce the allergenicity of soy protein 
(van de Lagemaat et al., 2007). Samples incubated for 9 and 19 days at 60°C and a aw of 
0.65 had the greatest reduction in immunoreactivity, 89.9% and 47.9% respectively, as 
determined by an ELISA, using polyclonal antibodies. The benefit to polyclonal 
antibodies is that information is provided about the effect of glycosylation on the 
allergenicity of all of the subunits of soy protein, not just a specific subunit as is the case 
when using monoclonal antibodies. Approximately 0.8% (w/w) of free amine was 
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reported after 19 days in comparison to 4.1% (w/w) free amine in the unincubated sample 
at day 0. No further information was provided about the extent of browning or the overall 
nutritional quality.  
The effect of glycosylation on protein functionality is dependent on the type of sugar 
used and the number of sugar residues that attach to the protein (Dunlap et al., 2005; Shu 
et al., 1996). The use of polysaccharides is particularly advantageous due to the steric  
hinderance imparted by the covalent of attachment of polysaccharides resulting in partial 
stability of the Amadori product, which prevents excessive browning. Polysaccharides as 
opposed to simple sugars result in greater functional changes to the modified protein, the 
extent of which depends on the hydrophilicity of the polysaccharide (Kato et al.,1992; 
Kato et al., 1993; Kato et al., 1990). Improvements in solubility, emulsification, and 
thermal stability have been reported for Maillard induced glycosylation of protein with 
polysaccharides (Jiménez-Castaño et al., 2005; Kato et al., 1993; Wang & Ismail, 2012). 
Negative consequences for nutritional quality and protein functionality have also been 
reported. The reaction conditions chosen for glycosylation will greatly influence the extent 
of lysine blockage, browning, and protein digestibility. Maximum losses in the essential 
amino acid lysine occur at 0.6-0.7 aw (Jokinen et al., 1976; Lea et al., 1949; Loncin et al., 
1968).  Extended incubation times even at unfavorable Maillard reaction conditions such 
as 37°C and 0.98 aw have led to significant losses (~10%) of lysine after just one week of 
incubation of casein in the presence lactose (Malec et al., 2002). In a casein-glucose model 
system, stored for 30 days at a temperature of 60°C at 0.2 aw and 0.5 aw, a 44% and 71% 
decrease in digestibility was reported (Culver et al., 1989), respectively. Storage for 10 
days at 0.65 aw and 50°C resulted in a 60% decrease in the solubility of ovalbumin using 
galactose (Kato et al., 1986). The biggest obstacle, therefore, to the usage of a 
glycosylated protein in a food product is the ability to tightly control the reaction and 
preventing propagation to late stages. 
While reductions in allergenicity have been achieved by Maillard induced 
glycosylation of soy protein, little data was reported about the feasibility of the 
ingredients in a food application, as there will most likely be quality issues, namely lysine 
blockage, excessive browning, and a loss of protein functionality.  Heating protein and 
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reducing sugars under dry conditions is considered preferable to the food industry as the 
long term stability of the product is not compromised and a dry product is easier to 
handle in comparison to a wet product (Oliver et al., 2006). However, long incubation 
times (< 2 weeks) are not practical for the food industry (Oliver et al., 2006). 
Furthermore, glycosylation conditions that promote the advancement of the Maillard-
reaction to advanced stages is another consideration for the feasibility of this reaction to 
reduce the allergenicity of soy. 
The by-products formed when Maillard-induced glycosylation is not properly 
controlled can have implications on human health such as increased complications 
associated with diabetes (Nguyen, 2006). The precursors for advanced glycation 
endproducts (AGE) are formed after the degradation of the Amadori compound in the 
intermediate stage to form α-hydroxycarbonyls (Poulsen et al., 2013). Precursor 
intermediates involved in color formation, AGE formation, and aroma development are 
formed from α-hydroxycarbonyls and include α-dicarbonyls, which favor AGE 
formation, 2-(amino-acid)-carbonyl compounds, which promote color, and 2-
aminocarbonyls, which promote aroma (Figure 1.4) (Yaylayan et al., 2004). Researchers 
believe that different “chemical switches” exist after α-hydroxycarbonyls have been 
formed that may promote color development instead of AGE formation (Poulsen et al., 
2013). However, due to the complexity of the advanced stage of the Maillard reaction the 
suspected “chemical switches” need to be identified. The type of AGE that can be formed 
depends on the sugar and amino acid involved in the Maillard-reaction. Examples of 
identified AGE products are presented in Figure 1.5.  
Advanced glycation endproducts that are formed in foods can be easily absorbed into 
the bloodstream, leading to protein crosslinking, which has a positive correlation with 
Type I and Type 2 Diabetes (Aso et al., 2000; Berg et al., 1998; Tan et al., 2004). 
Inflammation and oxidative stress markers, commonly considered risk factors for diabetes, 
have been found in individuals that consumed diets high in foods containing large 
amounts of AGE compounds (Berg et al., 1998). Therefore, the Maillard-reaction must be 
tightly controlled in order to prevent the formation of compounds hazardous to an 
individual’s health, prevent a high degree of lysine blockage, and lastly avoid excessive 
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color development.  
 
 
 
Figure 1.4. A sample of the intermediates involved in aroma, color, and AGE formation 
in food. 
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Figure 1.5 A Sample of advanced glycation endproducts formed from lysine and arginine. 
 
1.8 Benefits of Response Surface Methodology (RSM) for Process Optimization  
 
 
Response surface methodology (RSM) is traditionally employed in both academia 
and industry in order to optimize a process and to better understand the relationship 
between different variables and a desired outcome. The main benefit to the construction 
and implementation of a RSM as compared to a traditional factorial design is that fewer 
experimental conditions need to be tested, which is often desirable when several different 
factors of interest need to be explored at several different levels. This allows for both cost 
and time-savings for the experimenter.  A second benefit of RSM is that the conditions 
that result in the maximum or minimum response can be determined from the prediction 
equation generated after the data is fit to the appropriate model.  
Two different designs are commonly used with RSM: Central Composite (CCD) or 
Box-Behnekn. In both cases, the variables of interest and their corresponding levels, 
referred to as the natural form are converted into a coded form that expresses the 
deviation of the levels of each different variable from 0. The main advantage over a Box-
Low molecular weight
pyrraline
pentisidine
3-DG-H1
High molecular weight
Gold
CEL
G-H
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Behnken design is that in a central composite design extreme levels of the variables are 
explored (Myers et al., 2009). A Box-Behnken design may be chosen to avoid extreme 
values when there are equipment or process limitations. The center points in a CCD are 
replicated more frequently compared to a Box-Behnken design, giving the experimenter a 
better sense of the variability that might be seen during the experiments (Myers et al., 
2009). Prediction equations are generated for each type of design that will predict the 
optimum levels of the variables that will lead to a maximum or minimum response.  
Once the variables have been coded and the experiment has been completed, a 
response surface can then be fitted to the data. Response surfaces commonly take on one 
of three forms: first order, first order with interaction, or second order (Figure 1.6). In a 
first order response, the main effects of the model come from the different variables. In 
this model, there is no interaction between the variables in the model. The equation for a 
first order model, or main effects model is as follows: y=βo + βixj + βixj, where βo is the 
linear coefficient for the model and βixj represents the linear model term for each of the 
variables explored. The number of linear model terms is dependent on the number of 
variables explored. In the case of a model that is first order with interactions, the 
following equation is generated: y=βo + βixj + βixj + βijxij, where βo is the linear coefficient 
for the model and βixj  is the linear model term and a new term is included in order to 
represent the interaction, βijxij, representing the interaction among the variables. When 
interaction is incorporated into a response surface plot, curvature can then be assessed 
(Myers et al., 2009). A greater degree of curvature is found when the model is fit as 
second order (Myers et al., 2009).  When curvature is found in the data, the maximum or 
minimum point can be determined. The equation for the second order fit is as follows and 
now has interaction terms and quadratic levels for the variables as well: y= β0 + βixj + βixj 
+ + βijxixi + βixj
2 + βixj
2 
, where βo represents the linear interaction term, βixj represents the 
linear term for each of the variables of interest, βijxij represent the interaction among the 
variables followed by βixj
2
, which takes into account the quadratic level of the variables. 
In order to determine the appropriate fit, the lack of fit p-value is taken into account. If 
the lack of fit p-value is found to be insignificant then a higher order model fit is 
suggested.  
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Additional considerations are taken into account when selecting the appropriate model 
fit. Significance of the majority of terms found in the model is also an important factor to 
consider. The sequential model sum of squares p-value is looked at to aid in the 
determination of the number of significant model terms. Model selection is based on 
selection of a significant lack of fit (P ≤ 0.05) for the highest order polynomial, which 
implies that the greatest number of model terms are significant. Adjusted R
2
 values and 
the predicted R
2
 values can also be helpful in the selection of a model as well.  A smaller 
difference between the adjusted R
2
 and the predicted R
2 
suggests that the model has been 
fit correctly.  
Bu et al. (2009) used RSM to determine the effect of different experimental variables 
that influence the Maillard reaction such as protein to sugar ratio, temperature, and 
incubation time in order to reduce the allergenicity of the milk protein α-lactalbumin. Five 
different levels were explored for the three variables of interest. Normally, 243 
experimental conditions would need to be tested, but since RSM was used, a total of 23 
different experimental conditions were tested. Based on the prediction equation generated 
from this work, a 95% reduction in allergenicity of α-lactalbumin could be achieved under 
the following conditions: protein to carbohydrate ratio of 5.96:1, temperature of 52.8°C, 
and a time of 78h. The main benefit to using RSM for this work was that fewer 
experimental conditions were investigated, saving both time and experimental resources. 
An additional benefit of this work is that the researchers can better draw conclusions as to 
which experimental parameters, in particular, have the greatest influence on the 
allergenicity. The researchers found that the protein to carbohydrate ratio was the variable 
that most significantly influenced the reduction in allergenicity. 
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Figure 1.6. Response surface plots for various model fits including first order, 
first order with interactions, and second order. 
 
 
1.9 Methods to Assess Immunoreactivity  
 
 
Several different analytical techniques are utilized in order to determine the 
allergenicity of unmodified and modified protein. Enzyme-Linked Immunosorbent Assay 
(ELISA), a quantitative method, uses absorbance values in order to measure the degree of 
interaction between an antigen and primary antibody. A Western blot, on the other hand, 
provides a qualitative assessment of immunoreactivity by commonly using SDS-PAGE 
gel electrophoresis to separate proteins based on molecular weight. The extent of 
interaction between the primary antibody and different subunits found in the parent 
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protein can be visualized in a Western blot. Antibodies used in both methods can be 
polyclonal or monoclonal in nature. A monoclonal antibody will recognize only a single 
epitope present on a protein, while polyclonal antibodies will recognize several different 
epitopes. Monoclonal antibodies eliminate non-specific binding because the antibody can 
only bind to a single epitope, however they can be costly to produce (Goding, 1996). 
Polyclonal antibodies, on the other hand, are useful when trying to detect a protein of 
interest because they can bind to multiple epitopes (Howard et al., 2013). Non-specific 
binding can occur with polyclonal antibodies (Howard et al., 2013). Furthermore, the 
antibodies used in both assays are also classified as either primary or secondary. A 
primary antibody specifically targets the antigen of interest, while the secondary antibody 
detects the primary antibody, both of which come from a host species after its immune 
system has been exposed to a particular antigen.  Both primary and secondary antibodies 
can be monoclonal or polyclonal. If the secondary antibody is polyclonal it can also 
exhibit non-specific binding with the antigen so selection of proper secondary antibodies 
is critical.  
In the case of an indirect or direct ELISA, the antigen, which is traditionally a protein, 
is immobilized to a solid phase, commonly a polystyrene microtiter plate. The antigen 
absorbs to the polystyrene plate by hydrophobic interactions and passive adsorption 
(Crowther, 1995). A primary antibody, which can come from a variety of host species, is 
added to form a complex with the antigen. If the assay follows the direct format, the 
detection enzyme is linked to the primary antibody that complexes with the antigen. This 
assay format is often expensive due to the production cost of labeled primary antibodies. 
Any non-specific binding that may be related to the use of the secondary antibody is, 
however, eliminated in this method (Crowther, 1995). In an indirect ELISA format, a 
labeled secondary antibody is used for detection of the antigen-primary antibody 
complex. Signal amplification is a major advantage of an indirect ELISA formats due to 
the increased sensitivity resulting from the increased number of epitopes found on the 
primary antibody that the secondary antibody can bind to (Crowther, 1995).  Blocking is 
also done after absorption of the antigen or antibody to the polystyrene plate to prevent 
non-specific interactions. In both ELISA formats, a detection enzyme, commonly 
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horseradish peroxidase or alkaline phosphatase, is used due to the vast number of 
detection substrates available for chemiluminescent, colorimetric, or chemflourmetric 
detection. 
Another type of ELISA that is commonly utilized is the sandwich format. In this type 
of assay, the microtiter plate is first coated with an antibody. The antigen of interest is 
then added followed by another antibody. The main advantage to this type of ELISA is 
increased sensitivity for antigen-antibody detection as two different epitopes must be 
present so the antigen can attach to both antibodies. It is crucial that both antibodies work 
in combination to detect an antigen, otherwise results can be negatively affected as the 
antibodies that are involved in the sandwich must detect different epitopes present on the 
antigen. Song et al. (2008) used a sandwich ELISA to assess the allergenicity of different 
soy protein containing products using human plasma for detection of antigen-IgE 
binding. Human plasma was used as both the coating and capture antibody with no 
mention of whether or not testing was done to determine that the IgE was binding to 
different epitopes on the antigen and that no competition existed for antigen binding. 
Western blots are commonly used to provide a qualitative assessment of the 
immunoreactivity of a protein. In this method, proteins are commonly separated by SDS-
PAGE gel electrophoresis, which separates the proteins by size (King, 1998). However, 
proteins can be separated by other means, such as charge or size to charge ratio. The 
separated proteins are then transferred to either a nitrocellulose or a polyvinylidene 
difluoride membrane (PVDF). The proteins will adhere to the membrane via mainly 
hydrophobic interactions. Blocking is done in order to prevent interaction between 
primary and secondary antibodies and the transfer membrane. As in the ELISA, Western 
blots can also follow a direct or indirect format. When chemiluminescence is used, 
sensitivity is increased and multiple images of the blot can be taken (Alegria-Schaffer et 
al., 2009). This method is dependent on an enzyme substrate reaction. Peroxide is formed 
from hydrogen peroxide that reacts with horseradish peroxidase, which is the detection 
enzyme. Luminol is then oxidized by peroxide leading to the formation of 3-
aminophthalate, which will release light when it moves to a lower energy state. This light 
can be captured on an x-ray film. 
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When fluorescence is used, a light is emitted as a result of the release of photons as an 
excited molecule transitions back to the ground state. One concern with this technique is 
the high background that may result from the fluorescent capability of nitrocellulose and 
PVDF membranes (Alegria-Schaffer et al., 2009). However, the main advantage to the 
use of fluorescence is that different targets that are present in the same lane can be 
detected using different fluorescent markers instead of having to strip and re-probe the 
membrane as is the case when using chemiluminescence (Alegria-Schaffer et al., 2009). 
This technique also costs less in comparison to other techniques (Alegria-Schaffer et al., 
2009) 
 
1.10  Conclusions  
 
 
The number of adults with an allergy to soy in the United States is continuing to grow 
(Wilson, 2005). As a result, the utilization of soy protein ingredients may decrease as the 
incidence of soy allergies increases unless different techniques are explored to reduce or 
eliminate the allergenicity of soy protein. Current techniques, mainly enzymatic 
hydrolysis and Maillard-induced glycosylation have been successful at reducing the 
allergenicity of soy protein. However, the conditions utilized for both techniques have 
been extensive leading to a detrimental effect on protein quality, functionality, or flavor, 
thus, severely limiting the food applications. Limited hydrolysis can reduce the 
allergenicity of soy protein, but not to an adequate level, while functionality may be 
enhanced. Limited and controlled Maillard-induced glycosylation of soy protein can 
improve the functionality and reduce the allergenicity. Thus, the combination of limited 
hydrolysis and controlled Maillard-induced glycosylation will, for the first time provide 
information about the combined effects of two different protein modification techniques 
to aid in the development of a hypoallergenic soy protein ingredients.  
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2. OPTIMIZATION OF ENZYMATIC HYDROLYSIS OF SOY PROTEIN TO 
REDUCE THE ALLERGENICITY USING REPONSE SURFACE 
METHODOLOGY 
 
 
 
2.1 Overview 
 
Limited enzymatic hydrolysis of soy protein isolate (SPI) was done using Alcalase 
2.4L to produce soy protein hydrolysate (SPH) with reduced allergenicity. Considerable 
reductions in the immunoreactivity of the α’ and α subunits of β-conglycinin, a moderate 
reduction in the immunoreactivity of the β subunit of β-conglycinin and acidic chain of 
glycinin, and a limited reduction in the immunoreactivity of the basic subunit of glycinin 
was observed. Response surface methodology (RSM) was used to optimize the hydrolysis 
conditions including time, temperature, and enzyme to substrate ratio (E:S) for maximum 
% reduction in immnoreactivity using sera from five soy allergenic donors, while 
maintaining a limited degree of hydrolysis (DH). The DH response was fit as a second 
order model with time, temperature, enzyme to substrate ratio, temperature and enzyme 
to substrate ratio interaction, and enzyme to substrate ratio squared as significant model 
terms. Variability in the % reduction in immnoreactivity was observed among the sera. 
Thus, data obtained using each individual serum was fit as an individual response 
surface. Three of the sera were fit as first order models, while two of the sera were fit as 
second order models. In order to determine the optimized hydrolysis condition, 
constraints were added on the DH to ensure that it did not exceed 8%. The SPH produced 
under optimized hydrolysis conditions had a 20-52 % reduction in immunoreactivity, 
which varied depending on the sera used. Further protein modification is needed to result 
in a greater reduction in immunoreactivity. 
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2.2 Introduction 
 
The use of soy protein-based ingredients has grown tremendously as the food industry 
looks for economical protein ingredients with high nutritional value and pronounced 
functionality. Consequently, sales of soy-based products increased from $1 billion in 
1996 to over $5.2 billion in 2011 (Soyfoods Association of North America, 2009). The 
major drawback, however, to the continual growth in the utilization of soy protein 
ingredients is its allergenicity. In the United States, soy is recognized by the Food and 
Drug Administration (FDA) as one of the “Big 8” food allergens. About 0.5% of the U.S. 
population has an allergy to soy (Sicherer & Sampson, 2006).  Allergic reactions to soy 
are considered mild compared to peanut, and commonly include hives, rhinitis, and 
inflammation. Reports however, of anaphylactic shock have occurred resulting in death 
after consumption of soy containing foods (Foucard & Yman, 1999). The known 
threshold of soy that will elicit an immune response is in the range of 0.0013-500 mg 
(Becker et al., 2004). Strict avoidance of products containing soy is the only physician 
recommendation for individuals with an allergy to soy. The growing market demand for 
soy protein ingredients stresses the need to develop techniques that not only enhance the 
health benefits and functionality of soy protein, but also eliminate its allergenicity.  
Several different protein modification techniques have been used to reduce the 
allergenicty of soy such as thermal treatment and genetic modification. Although 
significant reductions in allergenicity have been reported, thermal treatment is highly 
variable and dependent on environmental factors including pH, temperature, length of 
heating, and ionic strength (Davis et al., 1998). Depending on the pH of the system 
glycinin, for example, may be found in either hexameric or trimeric complexes, 
impacting the conformation of the secondary and tertiary structure of the protein, which 
may result in the exposure or masking of IgE binding epitopes (Lakemond et al., 2000). 
Epitopes commonly consist of eight to eleven amino acids that can be formed as a result 
of protein folding, referred to as conformational, or they can be linear, i.e. a linear 
sequence of amino acids. Genetic modifications to remove the two major storage proteins 
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in soy, β-conglycinin and glycinin, has resulted in increased levels of free amino acids 
and the Gly m Bd 30 K fraction, which 65% of individuals with an allergy to soy are 
allergic to (Takahashi et al., 2003). 
Another commonly used technique to reduce the allergenicity of soy is enzymatic 
hydrolysis, which targets both linear and conformational IgE binding epitopes (L’Hocine 
et al., 2007; Lee et al., 2007; Tsumura et al., 1999). In some cases, protein hydrolysis has 
led to increased allergencity in comparison to the unmodified parent protein due to the 
exposure of IgE binding epitopes that were previously located in the interior moiety of 
the protein, and were thus, unaccessable for IgE binding (L’Hocine et al.,  2007).   
In order to produce a hypoallergenic ingredient following enzymatic hydrolysis, 
excessive hydrolysis needs to be achieved with a percent degree of hydrolysis (DH) 
greater than 40% (Tsumura et al., 1999). Extensive hydrolysis has a detrimental effect on 
protein functionality and flavor, thus severely limiting its use in food applications. The 
release of bitter peptides upon excessive hydrolysis is one of the biggest drawbacks to 
this protein modification technique (Alder-Nissens, 1986; Sun, 2011). Most commonly, 
protein solubility, gelation, and emulsifying properties are adversely affected at high 
DH’s. Selective hydrolysis of β-conglycinin with resulting 14% DH negatively affected 
emulsification (Tsumura et al., 2005). Increased hydrophobic interactions can occur as a 
result of exposure of hydrophobic residues upon hydrolysis, negatively affecting the 
solubility of soy protein, especially at a pH of 6 and less than 3.5 (Tsumura et al., 2005). 
Enzymes and/or associated hydrolysis conditions that prevent the exposure of new 
epitopes have yet to be determined.  
Controlled hydrolysis where the DH is maintained between 2-8% can prevent the 
release of bitter peptides and enhance protein functionality (Alder-Nissens, 1986), which 
allows for the usage of the modified ingredient in food applications. Such a limited DH 
might reduce allergenicity, but may not produce a hypoallergenic ingredient. This work 
will determine the effect of a controlled DH (between 2-8%) on the allergenicity of soy 
protein. Different enzymatic conditions such as incubation time, temperature, and 
enzyme to substrate ratio will need to be investigated.  
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In order to identify enzymatic conditions that lead to the production of a soy protein 
ingredient with reduced allergenicity, response surface methodology (RSM) will be used. 
There are numerous combinations of factors with multiple levels that must be explored to 
determine the hydrolysis conditions that will result in the maximum reduction in 
allergenicity at a DH between 2-8%. Response surface methodology (RSM) provides the 
benefits of testing fewer experimental units saving both experimental resources and time. 
Therefore, the objective of this work was to determine the optimal hydrolysis condtions 
for maximum reduction of soy protein allergenicity using RSM. 
 
 
2.3 Materials and Methods 
 
 
2.3.1 Materials 
 
 
Minimally heat-treated and defatted soy flour and Food Grade Alcalase 2.4L (2.4 
AU-A/g) was kindly provided by Archer Daniels Midland (Decatur, IL) and Novozymes 
(Denmark), respectively. Pre-stained broad-range molecular weight standard (161-0318), 
pre-stained low molecular weight standard (161-0377), Laemmli sample buffer (161-
0737), 10X Tris/Glycine/SDS running buffer (161-0732), TGX Precast Gels 4-20% (567-
1094), and peptide precast gel (345-0068) were purchased from BioRad (Hercules, CA). 
Biotinylated Mouse Anti-Human IgE (ab99807) was purchased from Abcam (Cambridge 
England). Polyvinylidene fluoride (PVDF) 0.2 µm (ISEQ00010) was purchased from 
Millpore (Billerica, MA). Enhanced chemiluminescenct substrate was obtained from 
(PI32106) from Pierce Scientific (Rockford, IL). Polystrene microplates (3370) were 
purchased from Corning (Tewksbury, MA). Goat anti-human IgE (16-10-04) was 
purchased from Kirkland and Perry Laboratories (Gaithersburg, Maryland). Streptavidin 
alkaline phosphatase (s2890), p-nitrophenol phosphate (N7653), and strepavidin 
peroxidase (s5512) were purchased from Sigma-Aldrich (St. Louis, MO). All other 
chemical grade reagents were purchased from Fisher Scientific (Waltham, MA). 
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2.3.2 Soy Protein Isolate (SPI) Production from Defatted Soy Flour  
 
Minimally heat-treated and defatted soy flour was used to prepare SPI  
following the method outlined by Margatan et al. (2013). A soy flour and double de-
ionized distilled water (DDW) dispersion (1:10 w/w) was prepared. The pH was adjusted 
to 7.5 with 2 N NaOH and stirred at room temperature for 1 hour. The solution was then 
centrifuged at 5000 x g for 30 min. The supernatant was adjusted to a pH 4.5 with 2 N 
HCl and centrifuged at 5000 x g for 10 minutes to precipitate the protein. The pellet was 
redispersed (1:4 w/w) in DDW, neutralized with 2 N NaOH, and lyophilized. The protein 
content of the lyophilized sample was 91.75% as determined following the Dumas 
method (AOAC 990.03) using a nitrogen analyzer (LECO, St. Joseph, MI). 
 
 
2.3.3 Experimental Design  
 
 
Soy protein isolate (SPI) was subjected to enzymatic hydrolysis by Alcalase 2.4L 
utilizing a central composite design (CCD) consisting of 3 different variables (Table 2.1). 
The variables selected for this work were temperature (x1), time (x2), and enzyme to 
substrate ratio (x3). The pH was held constant at 7.5, which is within the optimum range 
for Alcalase. A CCD design consists of an embedded factorial design and axial points. 
The axial points allow for an estimation of curvature in the data, which aids in 
determination of the maximum or minimum response. The distance from the center point 
to a factorial point is +/- 1, while the distance from the center to an axial point is +/- the 
absolute value of α. The design was generated using R 3.01.2 “Good Sport” and consisted 
of 20 different experimental runs with 6 center points, 8 factorial points, and 6 axial 
points (Figure 2.1, Table 2.2). Preliminary experiments were conducted to determine 
hydrolysis conditions that would lead to a DH between the targeted range of 2-8%. These 
conditions were set as the center point. The levels for the factorial points were selected to 
ensure that the temperature did not exceed the optimum for the Alcalase, the time was not 
too long, and the amount of enzyme was minimal. The time and enzyme levels chosen 
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were selected to make the process industry feasible with regard to enzyme cost and 
processing.  
 
 
Figure 2.1. Central Composite Design (CCD) consisting of 8 factorial points, 6 axial 
points, and 6 center points.  
 
 
 
Table 2.1. Natural and coded levels of the experimental variables for RSM with pH held 
constant at 7.5. 
 Coded Levels Natural Levels 
Temperature (°C), x1 -1.63 -1 0 1 1.63 38.67 45 55 65 71.33 
Time (minutes), x2 -1.63 -1 0 1 1.63 12.34 25 45 65 77.66 
E:S* (ml:100g), x3 -1.63 -1 0 1 1.63 0.06 0.1 0.2 0.4 0.62 
* Enzyme to substrate ratio 
 
 
 
 
 
 
 
 
 
 
6
Axial point 
Factorial point
Center point
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Table 2.2. Central Composite Design (CCD) for Alcalase 2.4 L Hydrolysis Conidtions. 
Run  Coded Levels 
   
Natural Levels 
 
   x1       x2        x3     x1       x2         x3 
1 -1 -1 -1 45 25 0.1 
2 1 -1 -1 65 25 0.1 
3 -1 1 -1 45 65 0.1 
4 1 1 -1 65 65 0.1 
      5 -1 -1 1 45 25 0.4 
6 1 -1 1 65 25 0.4 
7 -1 1 1 45 65 0.4 
8 1 1 1 65 65 0.4 
9 0 0 0 55 45 0.2 
10 0 0 0 55 45 0.2 
11 0 0 0 55 45 0.2 
12 0 0 0 55 45 0.2 
13 -1.63 0 0 38.67 45 0.2 
14 1.63 0 0 71.33 45 0.2 
15 0 -1.63 0 55 12.34 0.2 
16 0 1.63 0 55 77.66 0.2 
17 0 0 -1.63 55 45 0.06 
18 0 0 1.63 55 45 0.62 
19 0 0 0 55 45 0.2 
    20 0 0 0 55 45 0.2 
x1 represents temperature (°C); x2 represents time (min); x3 represents enzyme to 
substrate ratio (E:S) mL of enzyme : 100 g protein.  
 
The numerical value for the alpha points is typically computed with statistical 
software such as R, or determined by the equation of α = {2k}1/4, with k representing the 
number of factors. The alpha value (α = 1.63) for this work was calculated using R. The 
relationship between the independent variables and the responses, DH and % reduction in 
immunoreactivity was determined using Design Expert 8.0 software (Stat Ease, 
Minneapolis, MN). Response surface plots were generated using R Version 3.01.2 “Good 
Sport”. Prediction equations were generated for all responses with Eq. 2.1 as an example 
of a first order response, Eq. 2.2 as an example of a first order with interaction response, 
and Eq. 2.3 as an example of a second order response. The conditions at which the 
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responses were maximal/optimal were then determined to validate the model. To validate 
the model, experimental data was obtained using the predicted optimum levels. 
 
y= β0 + β1x1 + β2x2 + β3x3 + ε           Eq. 2.1 
 
 
y= β0 + β1x1 + β2x2 + β3x3 + β12x1x2 + β13x1x3 + β23x2x3   Eq. 2.2 
 
y= β0 + β1x1 + β2x2 + β3x3 + β12x1x2 + β13x1x3 + β23x2x3 + β1x1
2 + β2x2
2 + β3x3
2 
+ ε               
          Eq. 2.3 
 
y is the dependent variable (% Reduction in immunoreactivity or % DH), xi is the level of 
the independent variable, β0 is the linear coefficient predicted by the model, βi is the 
linear terms, βiXixi represents the interaction term, while βi
2
 represents the quadratic term 
predicted by the model, ε  is the error associated with the model.  
 
 
2.3.4  Patient Recruitment 
 
 
Patients with a reported allergy to soy were initially screen by reviewing skin prick 
and/or radioallergoabsorbent test (RAST) results found in their medical charts. Once a 
convincing history of an allergy to soy was confirmed, research participants were 
subjected to an initial blood draw. All clinical laboratory services for this work were 
provided by Clinical Translational Science Institute (CTSI) at the University of 
Minnesota. Serum samples were then sent to Quest Diagnostics (Woodale, IL) for testing 
to determine the soy specific IgE, IgE total, and IgG total. A total of 12 patients were 
screened and 5 with soy specific IgE levels of 3.5 kU/L or greater were chosen for 
participation in this project (Table 2.3). A soy specific IgE level of 3.5 kU/L or greater is 
considered a high level according to the manufacturer of the ImmunoCap assay that was 
used by Quest to determine soy specific IgE concentrations. Up to 100 mL of blood was 
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drawn at once or on multiple visits depending on the body weight. Sera was separated 
from whole blood by centrifugcation and stored at -80°C for later use in Western blots 
and ELISA to determine the immunoreactivity of the modified and non-modified soy 
protein.  
 
Table 2.3. Participants’ Sera Soy Specific IgE, IgE total, and IgG total levels.  
Participant IgE Soy Specific (kU/L) IgE Total (kU/L) IgG Total (mg/dL) 
1 0.35  189 1281 
2 <0.35 176  1040 
3
*
 5.61  606 840 
4 0.78  60  860 
5 0.63  137  992 
6
*
 20.90  1225  736 
7
*
 4.16  1728  1224 
8-Control <0.35   
9* 6.96 245 794 
10 0.60 103 1248 
11 <0.35 142 772 
12* 45.30 n/a n/a 
*Denotes patient sera utilized for this work 
 
 
 
2.3.5 Hydrolysis of SPI using pH Stat Method  
 
Soy protein isolate was subjected to enzymatic hydrolysis by Alcalase 2.4L following 
the pH-stat methodology (Alder-Nissens, 1986). A DL22 titrator (Mettler Toldeo, 
Columbus, OH) was used to conduct a series of end point titrations to a pH of 7.5 for the 
duration of the experiment. Dispersions of SPI in DDW (5% protein w/v) were prepared 
in triplicate and the pH adjusted to 7.5 with 0.2N NaOH. The dispersions were heated to 
38.67, 45, 55, 65, or 77.6 ºC for 15 min prior to the addition of Alcalase. Alcalase was 
added to obtain an enzyme to substrate ratio (E:S) ranging from 0.06:100 to 0.62:100 
(mL of enzyme to 100g of protein) (Table 2.2). While stirring, the pH of each dispersion 
was maintained at 7.5 throughout the incubation period, which ranged from 12.34-77.66 
min, by the addition of 0.2 N NaOH every 5 min. After the incubation was completed, the 
hydrolysates were subjected to boiling for 5 min in order to inactivate the enzyme. The 
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samples were lyophilized and analyzed for protein content using a nitrogen analyzer 
(LECO, St. Joseph, MI) following the Dumas method (AOAC 990.03) (Table 2.4).  
Lyophilized samples were kept at -20°C until further analysis. The  DH was calculated 
following the formula reported by Adler-Nissens (1986) (Eq. 2.4). A sample calculation 
is included in the Appendix A. 
 
 
%DH=(h/htot) x 100 = (B x Nb)/(MP x α x htot)          Eq. 2.4 
 
 
B is the volume of NaOH that is added in mL; Nb is the normality of the base; MP is the 
mass of the protein; htot is the total number of peptide bonds in the protein; and α is the 
degree of dissociation of the α-NH2 as determined by the incubation temperature.  
 
 
2.3.6 Sodium-Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 
Protein distribution of SPI and soy protein hydrolysate (SPH) was monitored 
following SDS-PAGE under reducing conditions as outlined by Laemmli (1970). Each 
sample was dissolved in DDW (~10.60 mg protein/mL), and an aliquot (100 µL) was 
mixed 1:1 (v/v) with Laemmli buffer under reducing (0.75 M β-mercaptoethanol) 
conditions and boiled for 5 min. Aliquots of samples (5μL) and pre-stained molecular 
weight standards (10μL) were loaded into wells of a pre-cast 4-20% TGX Criterion 
gradient gels or Criterion peptide gels. Gels were electrophoresised at 150V for 
approximately 1 hour and then were stained with staining solution (45% w/v methanol, 
10% glacial acetic acid w/v, 45% DDW w/v, and 3g/L Coomassie Brilliant Blue G-250) 
for one hour and destained overnight using destaining solution (10% glacial acetic acid 
w/v, 5% methanol w/v, and 85% DDW). Gels were scanned using Molecular Imager Gel 
Doc XR system (Biorad, Hercules, CA).  To determine the band intensities the image 
acquired from the Molecular Imager Gel Doc XR was uploaded into Image J following 
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the method outlined by Ge et al. (2010), with modifications. The image type was set to 8 
bit and the measurements were set to include integrated density, mean gray value, and 
area. The pixel to aspect ratio was set to 1.0 with the unit of length set to pixels. The 
image was inverted prior to analysis. The % reduction in band intensity was determined 
for several subunits in soy protein (Eq. 2.5). SDS-PAGE gels were analyzed in triplicate.     
 
% protein modification = 100 X (Corrected IntDSPI – Corrected IntDSPH)/(Corrected IntDSPI)                                      
                                            Eq. 2.5 
 
IntD is equivalent to the integrated density; Corrected IntDSPI is equivalent to (IntDSPI -
IntDbackground); Corrected IntDSPH is equivalent to (IntDSPH-IntDbackground). 
 
 
 
2.3.7 Western blot 
 
 
Western blots were performed to study the reactivity of soy specific IgE in sera from 
soy allergenic donors with SPH, following the method outlined by Eigenmann et al. 
(1996), with modifications. Samples were prepared as outlined under section 2.3.6. 
Aliquots (5 µL) were loaded into wells of a Criterion TGX Precast 4-20% gradient gel 
and electrophoresed at 100V for approximately 1 hour.  Transfer onto a PVDF membrane 
using transfer buffer (48 mM Tris, 39 mM Glycine, 20% Methanol w/v, 0.0375% w/v 
SDS) was done for 2 hours at room temperature at 300A. The membrane was soaked in 
methanol for 30 seconds prior to the transfer. In order to confirm a complete transfer, gels 
after transfer were stained with coomassie blue and scanned. Membranes were blocked 
by incubating with 0.5% bovine gelatin/phosphate buffered saline (PBS) (10 mM 
phosphate, 0.138 M NaCl, 2.7mM M KCl, pH 7.4)-Tween 20 (0.1% w/v) overnight at 
4°C on a shaker, followed by washing with PBS-Tween 20 (0.1%). The membranes were 
then incubated with serum (1:8-1:50 dilution) for 2 hours at room temperature on a 
shaker. Membranes were washed with PBS-Tween 20 (0.1% w/v) for 25 minutes, and 
then were incubated at room temperature with secondary biotinylated mouse anti-human 
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IgE (1:3000) for 1 hour on a shaker, followed by washing with PBS-Tween 20. 
Membranes were then incubated with streptavidin-peroxidase (diluted 1:2000 using 0.1% 
BSA/PBS w/v) for 30 min at room temperature on a shaker, and washed with PBS-
Tween 20. All blots were developed by enhanced chemiluminescent substrate (ECL) and 
scanned with a film processor. To determine the band intensities the image acquired from 
the Molecular Imager Gel Doc XR (Biorad, Hercules, CA) was uploaded into Image J as 
described in Section 2.3.6.  
 
 
2.3.8 Enzyme Linked Immunosorbant Assay (ELISA) 
 
An indirect ELISA was used to assess the immunoreacivity of SPI and SPH using 
sera from soy sensitive donors as outlined by Brandon et al. (2002), with modifications. 
Microtiter plates (96 wells) were coated with 100 μL of 5 μg protein/mL PBS of antigen 
(either SPI or SPH) was dissolved in PBS overnight at 4°C. Plates were washed 4 times 
in between each step using an automatic plate washer (Stat Fax, Orlando Florida) with 
PBST (PBS with 0.05% Tween 20 w/v). Blocking was done for 1 hour at room 
temperature using 200 μL/well of 3% w/v bovine serum albumin (BSA) + 0.05% w/v 
Tween 20. Diluted (1:10-1:50 using PBST), serum (100 μL) was added to each well and 
the plate was incubated for 1 hour at room temperature. Diluted (1:250 using tris buffered 
saline (TBS)), 50 mM Tris, 0.138 M NaCl, 2.7 mM KCl, pH 8.0, and .01% Tween 20, 
w/v) the secondary antibody (100μL) was added to each well and the plate was incubated 
for 1 hour at room temperature. This step was followed by the addition of diluted (1:500 
in TBS and 0.01% Tween 20, w/v) streptavidin alkaline phosphatase (100 μL to each 
well) and incubated for 30 minutes at room temperature. Lastly, p-nitrophenol phosphate 
(100 μL) was added to each well, and the plate was incubated for 30 minutes at room 
temperature. Absorbance was read at 405nm in a microplate reader (Biotek, Winooski, 
VT). Negative sera, only secondary antibody with no sera (to correct for non-specific 
binding), and blank (all reagents with no antigen) were run in this assay as controls 
(Figure 2.2). All analysis was conducted in triplicate. The % reduction in allergenicity of 
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the different hydrolysates was determined (Eq. 2.6). A sample calculation can be found in 
Appendix B.  
 
 
% Reduction in allergenicity = 100 x (Corrected ABSSPI – Corrected ABSSPH/Corrected ABSSPI) 
          Eq. 2.6  
 
ABS is the absorbance at 405nm; Corrected ABSSPI is equivalent to (ABSSPI positive sera – 
ABS2nd antibody); Corrected ABSSPH is equivalent to (ABSSPH positive l sera – ABS2nd antibody). 
 
 
 
 
Figure 2.2. Layout of different reaction mixtures for the ELISA assay to assess the 
immunoreactivity of the modified protein, including blank wells, negative control wells, 
2
nd 
antibody wells, and positive wells.  
 
 
 
 
 
 
Blank Wells: Positive human sera*, 
2nd antibody, streptavidin alkaline phosphatase, 
p-nitrophenol phosphate
*Sera from individual with soy specific IgE >3.5 kU/L
Negative Control Wells: antigen, negative control sera**,
2nd antibody, streptavidin alkaline phosphatase, 
p-nitrophenol phosphate
** Sera from individual with no medical history of
soy allergy 
2nd Antibody Wells:  antigen, 2nd antibody,
streptavidin alkaline phosphatase,
p-nitrophenol phosphate
Positive Control Wells: antigen, positive control
human sera*, 2nd antibody, streptavidin
alkaline phosphatase, p-nitrophenol
phosphate
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2.3.9 Statistical Analysis 
 
Response surface analysis was conducted using Design Expert 8.0 (Stat Ease, 
Minneapolis, MN) taking into account first order, first order with interactions, and second 
order model terms as defined in Section 2.3.3. Model fit was based on insignificant lack 
of fit p-value (p ≥ 0.05), significance of model sum of squares p-value (p ≤ 0.05) to 
determine if additional model terms were significant, and the adjusted R
2
 value. Three-
dimensional response surface plots for fitted second order and first order models were 
generated using R version 3.01.2 (2013-05-16) “Good Sport” by holding one independent 
variable constant and setting the other two independent variables to levels contained 
within the design space. Experimental data obtained for each individual serum was 
analyzed to assess model fit using analysis of variance (ANOVA) utilizing Design Expert 
8.0 ANOVA was also conducted using SPSS 15 for Windows. Differences between 
means were determined (P ≤ 0.05) using Tukey-Kramer multiple means comparison test. 
A summary of ANOVA tables can be found in Appendix E. 
 
 
2.4 Results and Discussion 
 
2.4.1 Protein Content and Profile Analysis of Produced Hydrolysates  
 
The protein content of the produced SPH samples ranged between 85-93%, while the 
% DH ranged from 1.13%-14.86% (Table 2.4). Protein profiling using SDS-PAGE 
(Figure 2.3) analysis confirmed the presence of the major allergenic components present 
in SPI including the two storage proteins β-conglycinin and glycinin. Upon hydrolysis of 
SPI using Alcalase, the bands corresponding to the α and α’subunits of β-conglycinin 
(68-72 kDa) disappeared while that corresponding to the β subunit (48 kDa) became 
fainter as the % DH increased (Figure 2.3). Densitometry analysis confirmed these 
observations (Table 2.5). Alcalase demonstrated more specificity toward the α and 
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α’subunits of β-conglycinin resulting in a 93.26% and 94.21% reduction respectively in 
the corresponding band intensitites at the highest DH. At moderate DH (6.12%), percent 
reduction in band intensity of α and α’subunits of β-conglycinin was 89.30% and 89.65%, 
repectively. A 46.16% reduction in band intensity was found for the β subunit for β-
conglycinin at the highest DH and a 30.60% reduction in band intensity was observed at a 
moderate DH (6.12%). Alcalase has been shown to have specificity toward the beta-
conglycinin subunits (Lee et al., 1990). Previous efforts to enzymatically hydrolyze SPI 
have resulted in the elimination of the β-conglycinin subunits. However, the extent of 
hydrolysis has been relatively high >28% (Tsumura et al., 1999).  
 
Table 2.4. DH and % Protein of the SPH Samples using Alcalase at Various Hydrolysis 
Conditions Hydrolyates.  
Condition (Time, 
Temperature, E:S)
B 
DH
C
(%) Hydrolysate 
Number  
 % Protein +/- SD
A 
25 min, 45°C, 0.1:100 1.13 1  93.6 +/- 0.1357 
12.38 min, 55°C, 0.2:100 2.00 2 92.7 +/- 0.317 
45 min, 55°C, 0.06:100 2.44 3 89.5 +/- 0.0212 
45 min, 38.67°C, 0.2:100 2.52 4 91.3 +/- 0.0544 
65 min, 45°C, 0.1:100 3.14 5 90.4 +/- 0.113 
25 min, 65°C, 0.1:100 3.46 6 90.7 +/- 0.619 
25 min, 55°C, 0.2:100 3.81 7 91.7 +/- 0.0431 
45 min, 55°C, 0.2:100 5.99 8 90.7 +/- 0.238 
65 min, 45°C, 0.4:100 6.12 9 90.9 +/- 0.496 
65 min, 65°C, 0.1:100 6.86 10 90.7 +/- 1.28 
45 min, 71.38°C, 0.2:100 7.59 11 90.5 +/- 0.909 
77.66 min, 55°C, 0.2:100 7.78 12 89.7 +/- 0.641 
25 min, 65°C, 0.4:100 9.69 13 89.0 +/ 0.197 
45 min, 55°C, 0.62:100 13.42 14 85.42 +/- 0.0111 
65 min, 65°C, 0.4:100 14.86 15 86.69 +/- 0.0511 
A 
SD: Standard Deviation; 
B
E:S: Enzyme to substrate ratio (mL of enzyme : 100 g protein) 
C
DH: degree of hydrolysis  
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The protein band corresponding to one of the acidic chains (33.4 – 42.2 kDa), 
specifically the A3 chain of glycinin got fainter as the DH increased (Figure 2.3). 
Densitometry analysis confirmed these observations (Table 2.5). For the SPH with the 
highest DH a 60.56% reduction in band intensity of the A3 chain and a 51.81% reduction 
in band intensity of the A1, A2, and A4 acidic chain was noted. At a moderate DH 
(6.12%), a 33.65% reduction in band intensity for the A3 acidic chain and a 23.05% 
reduction in intensity was found for the A1, A2, A4 acidic chain. Similar to what was 
reported by other researchers, (Lee et al., 2007), the basic subunit from of glycinin 
resisted enzymatic degradation and a maximum of 11.21% reduction in band intensity 
was found for SPH 14 (DH = 13.42%). 
 
Figure 2.3. SDS-PAGE gel of SPI and various hydrolysates at varying DH. Lane 1: 
molecular weight marker; Lane 2: SPI; Lane 3-18: hydrolysates, numbered 1-15 
corresponds to the SPH numbers found in Table 2.4. A: α’ (72 kDa); B: α (68 kDa) of β-
conglycinin; C: β (48 kDa) from β-conglycinin; D: glycinin A3 acidic chain (42 kDa); E: 
glycinin A1, A2, A4 33.6-37.0 acidic chain; F: glycinin basic chain. 
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Table 2.5 Extent of Protein Modification by Alcalase Determined by Measuring % 
Reduction in Intensity of the Different Protein Bands Using Densitometry.  
% Reduction in Band Intensity ± SD
A 
  β-conglycinin 
Sample  α' α            β 
SPH 1  51.00 +/- 12.91 37.61 +/- 2.047 0 
SPH 2 66.08 +/- 13.60 56.80 +/- 2.737 0 
SPH 3 53.43 +/- 8.734 38.87 +/- 0.4480 0 
SPH 4 65.69 +/- 7.491 60.83 +/- 1.462 0 
SPH 5  45.95 +/- 6.052 43.45 +/- 11.91 0 
SPH 6  63.22 +/- 3.974 57.93 +/- 6.158 21.39 +/- 2.457 
SPH 7  74.09 +/- 3.705 73.92 +/- 0.1156 6.496 +/- 1.132 
SPH 8 84.51 +/- 1.254 84.44 +/- 2.679 5.565 +/- 0.3383 
SPH 9  89.65 +/- 1.246 89.30 +/- 2.982 30.60 +/- 3.778 
SPH 10  77.57 +/- 0.3918 79.47 +/- 1.332  44.18 +/- 0.7131 
SPH 11  80.14 +/- 1.883 83.44 +/- 1.770 52.72 +/- 3.221 
SPH 12  83.96 +/- 0.1538 85.67 +/- 1.886 27.96 +/- 2.560 
SPH 13 84.86 +/- 2.325 86.82 +/- 0.8846 33.67 +/- 0.1912 
SPH 14 91.94 +/- 0.7980 93.22 +/- 1.560 52.04 +/- 1.320 
SPH 15 93.26 +/- 1.130 94.21 +/- 0.0706 46.18 +/- 3.844 
    
 Glycinin 
Sample  A3 A1, A2, A4 Basic 
SPH 1  9.406 +/- 2.192 3.996 +/- 3.170 2.064 +/- 5.058 
SPH 2 10.63 +/- 3.132 7.076 +/- 2.300 2.108 +/- 4.047 
SPH 3 8.557 +/- 3.139 3.669 +/- 3.302 1.722 +/- 4.378 
SPH 4 7.306 +/- 4.910 6.663 +/- 5.055 0 
SPH 5  0 4.990 +/- 4.699 0 
SPH 6  13.79 +/- 2.622 7.489 +/- 4.411 0.6765 +/0 1.662 
SPH 7  10.81 +/- 2/098 12.13 +/- 0.8275 0.8438 +/- 0.8900 
SPH 8 19.88 +/- 3.924 13.22 +/- 2.377 1.727 +/- 0.6550 
SPH 9  33.65 +/- 0.7440 23.05 +/- 2.167 12.04 1.190 
SPH 10  31.38 +/- 1.465 16.65 +/- 2.255 6.625 +/- 3.976 
SPH 11  24.09 +/- 0.3431 11.67 +/- 3.851 2.908 +/- 3.883 
SPH 12  28.22 +/- 1.959 20.85 +/- 4.057 3.259 +/- 4.813 
SPH 13 39.08 +/- 0.7679 25.64 +/- 0.4561 4.263 +/- 4.397 
SPH 14 56.53 +/- 1.630 51.81 +/- 0.2458 11.21 +/- 1.177 
SPH 15 60.56 +/- 0.3373 45.05 +/- 0.9066 8.791 - 1.728 
A
SD: standard deviation. 
*Band Intensity was determined by using Eq. 2.5. % Reduction in band intensity was an 
average of 3 replicates. 
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2.4.2 Effect of Hydrolysis Conditions on the Immunoreactivity 
 
 Sera from allergenic donors with varying soy specific IgE levels was used for 
qualitative and quantitative assessment of the imunoreactivity of SPH produced at the 
various enzymatic conditions following the Western blot and ELISA,  respectively. The 
reduction in immunoreacitivty of SPH was dependent on the enzymatic conditions and 
the sensitivity of the sera used. Major allergenic compounds in SPI demonstrated the 
greatest immunoreactivity including α’, α, and β subunits of β-conglycinin, acidic chains 
and the acidic and basic chains of glycinin (Figure 2.4 and Figures 5.1 - 5.3 Appendix C). 
The band intensities of the allergenic subunits in SPH samples (Lane 3-18) were 
compared relative to their counterparts in SPI. The α’ and α subunits of β-conglycinin 
had minimal/undetectable reactivity upon hydrolysis, the extent of which varied 
depending on the sera used. When using serum from patient 9 (Figure 2.4 B), 
immunoreactivity of the α subunit of β-conglycinin was detected for SPH 1-SPH 6 (DH < 
3.46%) and SPH 10 (DH = 6.86%) (Table 2.7). However, a significant reduction, 
93.30%, in band intensity was observed using the sera from patient 9 for SPH 10 (Table 
2.7). In comparison, no immunoreactivity for the α’ and α of β-conglycinin was detected 
when using serum from patient 6 or patient 12, 7, or 3 (Figure 2.4 A and Figures 5.1 - 5.3 
Appendix C).   
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Figure 2.4. Western blots using different sera showing the immunoreactivity of SPI and 
SPH 1-15. The SPH numbering corresponds to those presented in Table 2.4. A)Western 
blot using sera from patient 6 (soy specific IgE 20.90 kU/L); B) Western blot using sera 
from patient 9 (6.96 kU/L soy specific IgE); A: α’ (72 kDa); B: α (68 kDa) of β-
conglycinin; C: β (48 kDa) from β-conglycinin; D: glycinin A3 acidic chain (42 kDa); E: 
glycinin A1, A2, A4 33.6-37.0 acidic chain; F: glycinin basic chain. 
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In general, the immunoreactivity of the β subunit of β-conglycinin decreased, as 
noted by the decrease in the intensity of the bands in the western blot (Figure 2.4 A) with 
few exceptions. Specific hydrolysis conditions may result in different hydrolysis patterns 
and therefore different resulting immunoreactivity. Using sera from patient 6, the 
immunoreactivity of the β subunit from β-conglycinin in SPH 1-8 (DH < 5.99%)  
remained relatively the same, with the % reduction in band intensities ranging from 
25.23% - 39.96% (Figure 2.4 A and Table 2.6). However, the immunoreactivity of the β 
subunit was lower for SPH 9 (DH = 6.12%) and SPH 11 (DH = 7.59%) when using the 
sera from patient 6. Using the sera from patient 9, the immunoreactivity of the β subunit 
across the different SPH samples (Table 2.7) varied considerably, and no particular trend 
was observed with the increase in DH. The hydrolysis conditions, not % DH, in this case, 
had an effect on the immunoreactivity of β-conglycinin.  
While the immunoreactivity of the α and α’ subunits of β-conglycinin was reduced 
considerably (Figure 2.4), the immunoreactivity of the β subunit was marginally reduced. 
Limited information is available about the specific type of sugars that are attached to the 
different subunits in β-conglycinin. However, the presence of two mannose containing 
glycans have been found in the α and α’ subunit where only one mannose glycan has 
been found in the β subunit (Doyle et al., 1986; Thanh and Shibasaki, 1977). The type of 
sugar that is attached to the protein has a potential relationship with its allergenicity. 
Some researchers have found that β (1,2)-xylose sugar moieties, which may be present in  
β-conglycinin have the capability to bind IgE (Kimura et al., 1997), while others have 
reported that a combination of both α-(1,3)-fucose and β (1,2)-xylose bound to amino 
acids, which also may be found in β-conglycinin, can serve as potential epitopes. More 
extensive work is needed to determine which particular subunits in β-conglycinin (α’, α, 
and β) these previously mentioned sugars may be attached to. The presence of sugars 
does not only influence IgE reactivity, but it may also influence the susceptibility of β -
conglycinin to hydrolysis. 
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Sugar moieties can protect a protein from enzymatic degradation by limiting the 
accessibility of the enzyme to protein cleavage sites for an enzyme (Amigo et al., 2011). 
This effect has been observed for the α and β subunits in β-conglycinin (Amigo et al., 
2011) and explains the reason why reactivity of the β subunit was still observed in this 
work. Western blots revealed that immunoreactivity was still detected after hydrolysis for 
the α and β of β-conglycinin. The α’ subunit appeared to be more easily accessible for 
enzyme cleavage. This suggests that the immunoreactivity detected for patient 9 (Figure 
2.4 B) is most likely the α subunit of β-conglycinin. The location of a sugar moiety 
relative to a potential enzyme cleavage site can limit the accessibility of an enzyme, 
which has been observed for other glycoproteins. The proximity of the sugar moiety to 
specific cleavage sites for Alcalase may explain why moderate reductions in 
immunoreactivity of β subunit of β-conglycinin were observed.  
Reductions in the immunoreactivity of glycinin were also observed after hydrolysis. 
The band corresponding to the immunoreactivity of A3 acidic subunit of glycinin was got 
fainter as the %DH increased with exceptions (Figure 2.4 A, and Figure 5.1, 5.2, and 5.3 
Appendix C). This subunit was not immunoreactive when using the sera from patient 9 
demonstrating that different individuals with an allergy to soy have immunoreactivity 
toward different subunits in SPI. A reduction in the band intensity corresponding to the 
A3 acidic subunit for SPH 1 (DH = 1.13%) was noted with a gradual increase in DH up 
to 6.12%, when using sera from patient 6 (Figure 2.4 A and Table 2.6). For SPH 10 and 
11 (% DH = 6.86 and 7.59% respectively) the % reduction in band intensity was only 
20.15% and 17.67%. Changes in immunoreactivity of the A1, A2, A4 acidic chains of 
glycinin varied across the sera from patient 6 and 9. The % reduction in band intensity 
corresponding to the A1, A2, and A4 acidic chains of glycinin when using sera from 
patient 6, for example, ranged from 30.64% - 34.57% for all SPH samples (Table 2.6). In 
comparison, the % reduction in band intensity when using sera form patient 9, increased 
with increasing DH for all samples achieving a % reduction in band intensity of 39.67% 
at a moderate DH (DH = 6.12) and a 90.50% reduction (Table 2.7) in band intensity at 
the highest DH. Minimal reductions in the immunoreactivity of the basic subunit from 
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glycinin were observed regardless of the sera used (Figure 2.4 A and B, Figure 5.1, 
Figure 5.2, and Figure 5.3 Appendix C). However, a reduction in band intensity 
corresponding to the basic subunit using the serum from patient 9 was observed for SPH 
14 (46.99%) and SPH 15 (41.59%).  
The immunoreactivity of the glycinin subunits was greater than that of the β-
conglycinin subunits after hydrolysis with Alcalase. Disulfide bonds hold a monomer 
consisting of an acidic and basic subunit of glycinin together, thus affecting the protein’s 
susceptibility to enzymatic cleavage (Breiteneder et al., 2000). The basic subunit, for the 
most, part remained reactive regardless of the extent of hydrolysis. The resistant to 
enzymatic hydrolysis exhibited can be attributed to its increased hydrophobicity and 
compact structure (Khang et al., 1988). 
 
Table 2.6. % Reduction in band intensity from the Western blot developed using 
 sera from Patient 6 (soy specific IgE 20.90 kU/L). 
% Reduction in band intensity 
 β-Conglycinin Glycinin 
Sample  α' α β A3 A1, A2, A4 Basic 
SPH 1  - - 36.07 59.4 30.64 19.95 
SPH 2  - - 20.57 24.78 20.44 13.22 
SPH 3  - - 20.98 26.87 20.44 17.76 
SPH 4  - - 32.22 37.95 22.14 12.51 
SPH 5  - - 33.13 34.97 22.32 16.57 
SPH 6  - - 31.66 34.22 25.59 0 
SPH 7  - - 39.96 39.95 22.37 0 
SPH 8  - - 25.23 46.61 22.92 0 
SPH 9  - - 59.44 64.94 29.22 0 
SPH 10  - - 31.29 20.15 20.24 0 
SPH 11 - - 71.64 17.67 20.63 0 
SPH 12  - - 46.14 34.38 24.79 0 
SPH 13  - - 48.84 59.4 29.48 0 
SPH 14  - - 57.44 86.36 36.96 0 
SPH 15  - - 51.88 93.25 34.57 0 
*Band Intensity was determined by using Eq. 2.5. % Reduction in band intensity was determined 
using a representative blot from the sera. 
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Table 2.7. % Reduction in band intensity from the Western blot developed using the sera 
from patient 9 (soy specific IgE 6.96 kU/L). 
 % Reduction in band intensity 
  β-Conglycinin Glycinin  
Sample  α' α β A2,A3, A4 Basic 
SPH 1  - 80.86 26.91 7.372 0 
SPH 2  - 82.01 4.892 16.97 0 
SPH 3  - 70.42 1.897 19.28 0 
SPH 4  - 84.19 1.172 11.42 0 
SPH 5  - 79.89 1.804 15.57 0 
SPH 6  - 87.77 24.07 20.83 0 
SPH 7  - - 34.48 44.43 5.467 
SPH 8  - - 14.45 31.08 0 
SPH 9  - - 25.16 39.67 0 
SPH 10  - 93.30 41.25 38.17 0 
SPH 11 - - 61.97 35.77 0 
SPH 12  - - 27.77 50.65 0 
SPH 13 - - 24.51 68.1 23.92 
SPH 14  - - 58.55 91.47 46.99 
SPH 15 - - 77.15 90.50 41.58 
*Band Intensity was determined by using Eq. 2.5. % Reduction in band intensity was 
determined using a representative blot from the sera. 
 
Different trends in the immunoreactivity were observed when serum from different 
patients was used. The observed differences can be attributed to the variation in different 
epitopes present in soy protein that soy specific IgE from different sera may react with. 
Different enzymatic conditions altered the structure of epitopes that prevented IgE 
binding for some sera but not all. For example in our western blots, sera from patient 9 
had a soy specific IgE level of 6.96 kU/L and exhibited no immunoreactivity toward the 
A3 acidic subunit of glycinin, while patient 6 had a soy specific IgE level of 20.90 kU/L 
and showed immunoreactivity toward the A3 subunit. Pedersen et al. (1989) reported that 
only the acidic subunits can illicit IgE binding, while Helm et al. (2000) observed that 
both the acidic and basic subunits of glycinin are immunoreactive. Immunoreactivity was 
detected for all three subunits of β-conglycinin in our study confirming the findings of 
Burks et al. (1989). However, Ogawa et al. (1995) reported that the α’ does not exhibit 
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immunoreactivitiy. Discrepancies in the reactivity observed in our study and others’ is 
attributed to patient age and sensitization history.  
The immunoreactivity of the modified soy protein began to shift toward lower 
molecular weight peptides (Figure 2.4 A, and Figures 5.1 - 5.3 in Appendix C). As noted 
when using the sera from patient 3, 6, 7, 9 and 12, no immunoreactivity was detected for 
SPI below 20 kDa (Figure 2.4, Figures 5.1 - 5.3 Appendix C). However, as the DH 
increased, immunoreactivity was detected below 20 kDa. As the DH increased, epitopes 
found within the interior of the protein when using sera from patient 3, 6, 7, and 12 may 
have gotten exposed or new epitopes were formed. For example, when using sera from 
patient 6, dark bands below 20 kDa were observed for SPH 6, and appeared more 
prominent with increasing DH (Figure 2.4 A).  A peptide specific SDS-PAGE gel was 
used to visualize lower molecular weight peptides (Figure 2.5). One band was observed 
below 20 kDa in SPI. As the DH increased, more peptides with molecular weights < 20 
kDa were observed in regions close to where the immunoreactivity was noted in the 
Western blots. While reduced immunoreactivity was noted in the molecular weight 
region of the original subunits, some of the resulting peptides post hydrolysis remained 
immunoreactive. This observation indicated that epitopes may not have been cleaved and 
remained present in the smaller molecular weight peptides.  
 
Figure 2.5. SDS-PAGE peptide gel with molecular weight standard, SPI, SPH 1-15 
(Table 2.4). 
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An indirect ELISA was used to obtain quantitative immunoreactivity data as well as 
assess the overall immunoreactivity of the modified protein. Significant reductions in 
immunoreactivity was observed upon hydrolysis of SPI (Figures 2.6 and 2.7 and Figures 
5.4 – 5.6 in Appendix C). The hydrolysis conditions that yielded the greatest reduction in 
immunoreactivity was similar across the different sera, with SPH 10 (DH = 6.86) having 
the most pronounced effect. However, maximum % reduction observed varied across the 
immunoreactivity of the sera used. Additionally, as the DH increased beyond the DH of 
SPH 10, % reduction in immunoreactivity remained the same or decreased (Figures 2.6 
and 2.7). Significant differences between SPH 10, which had the highest % reduction in 
immunoreactivity, and SPH 15, which had the highest DH was observed when using the 
sera from patient 12. Two mechanisms occur when enzymatic hydrolysis is employed to 
alter the immunoreactivity of a protein. Exposure of epitopes buried within the interior of 
the protein may occur simultaneously as linear and conformational epitopes are destroyed 
upon hydrolysis. The significantly lower % reduction in immunoreactivity observed for 
SPH 15 compared to that of SPH 10 (Figure 2.7) suggested that the exposure of 
previously unacessable epitopes was greater than the extent of linear and conformational 
epitope breakdown. Using sera from other patients, such as patient 7 the breakdown and 
exposure of epitopes appeared to be balanced upon hydrolysis (Figure 2.6). 
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Figure 2.6. % reduction in immunoreactivity of SPH samples 1-15 following ELISA 
using sera from patient 7 (soy specific IgE of 4.16 kU/L). Error bars represent standard 
error. Different lower case letters above the bars indicate significant differences between 
the means according to Tukey-Kramer multiple means comparison (P ≤ 0.05); n=3. 
Analysis of variance (ANOVA) table is found in Appendix E. 
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Figure 2.7. % reduction in immunoreactivity of SPH samples 1-15 following ELISA 
using sera from patient 12 (soy specific IgE of 45.90 kU/L). Error bars represent the 
standard error. Different lower case letters above the bars indicate significant differences 
between the means according to Tukey-Kramer multiple means comparison (P ≤ 0.05); 
n=3. Analysis of variance (ANOVA) table is found in Appendix E. 
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Conformation of a protein influences its immunoreactivity as certain conformational 
or linear epitopes may be exposed. Characterization of epitopes can provide insight into 
how both linear and conformational epitopes respond to protein modification techniques. 
Enzymatic hydrolysis is believed to primarily target conformational epitopes, which are 
formed based on protein folding (Lee et al., 2004; Lee et al., 2007). However, it can also 
target linear epitopes. Researchers have identified linear IgE binding epitopes in glycinin 
(G1 and G2) and the P34 subunit in soy (Figure 2.8). Thus, it is plausible to speculate 
whether linear epitopes may have been cleaved based on the amino acid specificity of the 
enzyme used for hydrolysis. Alcalase 2.4L is an endo-peptidase with specificity toward 
aromatic amino acids such as phenylalanine, tyrosine, and tryptophan (Doucet et al., 
2003). Alcalase may also be specific for other amino acids including glutamic acid, 
methionine, leucine, alanine, serine, and lysine (Doucet et al., 2003). It is likely that some 
linear epitopes were destroyed upon hydrolysis with alcalase due to the high abundance 
of leucine in the known epitopes. The presence of serine, phenylalanine, tryptophan, and 
alanine, although found in a lower proportion may also been cleavage sites for alcalase. 
No epitope mapping was conducted, so definitive conclusions cannot be made about 
which particular enzymatic conditions may have led to the cleavage.  
Hydrolysis using Alcalase resulted in elimination of IgE binding epitopes in major 
allergenic components in soy including β-conglycinin and glycinin. During hydrolysis, a 
dual mechanism exists; epitopes found in the interior of the protein are exposed, while 
epitopes found on the exterior of the protein are cleaved. Depending on the sensitivity of 
the sera to specific epitopes exposed, one component of the dual mechanism may 
dominate upon protein unfolding due to hydrolysis. Thus, protein confirmation, which is 
affected by hydrolysis, greatly influences the immunoreactivity. Optimization of 
hydrolysis conditions that lead to maximal reduction in immunoreactivity, while 
controlling the DH, is needed to develop a hypoallergenic protein ingredient. 
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Table 2.8. Identified linear epitopes in G1, G2, and P34*.  
Linear epitopes present in G2 subunit from glycinin  
Position AA 3-17 AA 83-97 AA 90-104 AA 177-191 
Sequence KLVLSLC 
FLLFSGCF 
NGPGEIYI 
QQGNGIF 
QQGNGIFG 
MIFPGCP 
RFLAGNQE 
QEFLKY 
     
Position  AA 189-203 AA 255-269 AA 337-351 AA 345-359 
Sequence LKYQQQQ 
QGGSQSQK 
VKGGLRV 
TAPAMRKP 
LDFPALWL 
LKLSAQY 
LKLSAQYG 
SLRKNAM 
     
Position AA 358-372 AA 367-381 AA 469-475  
Sequence MFVPHYT 
LNANSIIY 
NANSIIYA 
LNGRALV 
QHTFNLKS 
QQARQVK 
 
     
     
Linear epitopes present in G1 subunit from glycinin  
Position  AA 217-235 AA 253-265   
Sequence GGSILSGFTL 
EFLEHAFSV 
GAIVTVKG 
GLSVI 
  
     
     
Linear epitopes present in P34 
Position  AA3-12 AA24-33 AA41-50 AA61-70 
Sequence FLVLLLFSLL RSILDLDLTK SSLFQLWSE EAKRLEIFKN 
     
Position  AA67-76 AA100-110 AA108-117 AA138-147 
Sequence  IFKNNSNYIR PQEFSKKTYQ YLQAPKDVSQ ASWDWRKKGV 
     
Position  AA144-153 AA109-208 AA218-227 AA223-232 
Sequence  KKGVITQVKY NGWHYQSFEW TDDDYPYRAK YRAKEGRCKA 
     
Position AA229-238 AA271-280 AA299-308 AA331-340 
Sequence  RCKANKIQDK ISVSIDAKDF INHFVLLVGY GYIWIQRNTG 
Bolded sequences denote immunodominant epitope. * Helm et al. (1998 and 2000) 
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2.5 Response Surface Modeling for the % DH and % Reduction in 
Immunoreactivity  
 
Response surfaces with appropriate model fit were used to assess the influence of 
three independent variables (time, temperature, and E:S) on the % DH and % reduction in 
immunoreactivity of the hydrolysates. Data obtained from the ELISA assay was used to 
determine the % reduction in immunoreactivity. Model selection was first based on an 
insignificant lack of fit p-value (P ≥ 0.05) for different responses including first order, 
first order with interactions, and second order. When a model was found to be significant 
the next highest order model was chosen. When an insignificant lack of fit p-value was 
not found for any models, the model sum sequential p-value was taken into consideration, 
which provides information about the number of terms included in the model that are 
found to be significant. The sequential model sum of squares analysis is dependent on the 
F value. A large F value for a model implies that at least one variable has a significant 
effect on the model. The F model value is calculated by MSmodel/MSerror. Thus, individual 
terms in a model such as linear, interactions, and second order were tested for 
significance (P ≤ 0.05) in order to determine their influence on the model. The highest 
order model that included the greatest number of significant model terms was selected, as 
a greater number of significant model terms are desirable to assess which factors affect 
the greatest effect on the response variable. The highest order model with a significant (P 
≤ 0.05) model sum of squares p-value was chosen. Lastly, a high adjusted R2 is desired as 
it signifies the power of the model. The models generated were used to determine the 
optimized hydrolysis conditions that would lead to the greatest reduction in 
immunoreactivity while the DH would not exceed 8%. 
 
2.5.1 Response Surface Modeling for % DH 
 
The DH was fit as a second order model as demonstrated by the equation in Table 
2.9. Lack of fit p-values for first order, first order with interactions, and second order 
were all found to be significant, as the p-values were less than .05 (Table 2.10). Thus, 
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selection of the second order model was justified by analysis of the sequential model sum 
of squares p-value (Table 5.3 Appendix F). A significant lack of fit for the highest order 
model, which was determined to be the second order model, had the greatest number of 
significant model terms. In this case, significant model terms included time, temperature, 
E:S, temperature and E:S interaction, and E:S squared. The second order model also had 
the highest adjusted R
2
, 0.95, as compared to 0.90 for a first order with interaction fit 
(Table 2.10). The second order model was used to generate the RSM plots shown in 
Figure 2.8. Actual vs. predicted responses for the second order model can be found in 
Table 2.11.  
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Table 2.9. Equations derived from RSM models with the best fit for the prediction of the 
dependent variables (Y1-Y6), with temperature as A, time as B, and enzyme to substrate 
ratio (E:S) as C on the log base 2 scale. All equations represent levels of the variables in 
the coded form. 
Response  Fitted Equation Adjusted 
R
2 
p-value 
DH (SO
A
) Y1= y=6.23 + 2.16A + 1.66B + 
2.77C +0.48AB + 1.02AC + 
0.27BC - 0.40A
2 – 0.41B2 + 
0.59C
2 
 
0.9454 0.0004 
    
% reduction in 
immunoreactivity 
sera from patient 3 
(FO
B
) 
Y2=40.33 + 6.46A + 8.23B + 
6.76C 
0.5034 0.0050 
    
% reduction in 
immunoreactivity 
sera from patient 6 
(SO
A
) 
Y3=28.17 + 5.54A + 7.79B + 
2.42C -0.45AB – 6.95AC -
1.38BC -0.38A
2 
-4.05B
2 
-2.66C
2
          
0.7857 0.3021 
    
% reduction in 
immunoreactivity 
sera from patient 7 
(SO
A
) 
Y4=45.40 + 6.46A + 9.43B + 
7.97C + 2.30AB – 5.02AC – 
4.32BC – 1.67A2 – 3.17B2 – 
3.87C
2 
 
 
0.8467 0.1964 
    
% reduction in 
immunoreactivity 
sera from patient 9 
(FO
B
) 
Y5=22.00 + 7.87A + 4.08B + 
6.26C 
0.5444 0.0641 
    
% reduction in 
immunoreactivity 
sera from patient 
12 (FO
B
) 
Y6 = 22.47 + 5.61A + 8.21B 
+ 4.05C 
  
0.5601 0.3985 
A
SO: second order; 
B
FO: first order 
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Table 2.10 Analysis of Variance (ANOVA) for RSM data  
Response Model SS DF MS F Lack of 
Fit p-
value 
Adjusted 
R
2 
DH FO
A 
26.68 11 2.43 86.39 <0.0001 0.8600 
 FO + 2WI
B 
15.88 8 1.98 70.68 0.0001 0.8971 
 SO
C 
6.400 5 1.28 45.60 0.0004 0.9454 
        
3
G 
FO
A
 1426 11 129.63 13.45 0.0050 0.5034 
 FO + 2WI
B
 1031 8 128.91 13.37 0.0055 0.5541 
 SO
C
 703.6 5 140.73 14.60 0.0053 0.5963 
        
6
H 
FO
A
 852.8 11 77.53 3.95 0.0705 0.5066 
 FO + 2WI
B
 449.7 8 56.21 2.86 0.1307 0.6501 
 SO
C
 160.0 5 32.01 1.95 0.3021 0.7857 
        
7
I 
FO
A
 921.4 11 83.77 4.70 0.0501 0.6663 
 FO + 2WI
B
 528.2 8 66.03 3.70 0.0828 0.7491 
 SO
C
 201.1 5 40.22 2.26 0.1964 0.8467 
        
9
J 
FO
A
 879.8 11 79.98 4.15 0.0641 0.0544 
 FO + 2WI
B
 515.8 8 64.47 3.35 0.0996 0.6484 
 SO
C
 391.5 5 78.24 4.06 0.0751 0.6359 
        
12
K 
FO
A
 673.7 11 61.25 1.33 0.3985 0.5601 
 FO + 2WI
B
 322.1 8 40.27 0.87 0.5890 0.6691 
 SO
C
 185.1 5 37.02 0.080 0.5920 0.6765 
A
 FO: First order; 
B
FO + 2 WI: first order plus two way interaction;  
C
SO: Second order; 
D
 SS: sum of squares; 
E
DF: degrees of freedom; 
F
MS: mean squares 
G
3: % 
reduction in immunoreactivity using sera from patient 3 
H
6: % reduction in immunoreactivity 
using sera from patient 6 
I
7: % reduction in immunoreactivity using sera from patient 7 
J
9: % 
reduction in immunoreactivity using sera from patient 9 
K
12: % reduction in immunoreactivty for 
sera from patient 12. 
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Table 2.11. Actual (A) and predicted (P) responses for the 20 hydrolysates obtained 
using Alcalase for the response variable DH, % reduction in immunoreactivity from 
serum 3, and % reduction in immunoreactivty from sera 6. 
 
 Run         Coded Levels* 
  
  
         DH Serum from 
patient 3 
Serum from 
patient 6  
      x1          x2             x3        A             P   
 
  A               P                       A     P  
1 -1 -1 -1 1.17 1.19 12.2 18.8 0 -3.64 
2 1 -1 -1 3.64 2.50 39.0 31.8 23.0 22.2 
3 -1 1 -1 3.12 3.01 36.4 35.3 18.3 16.0 
4 1 1 -1 6.77 6.24 49.2 48.2 36.1 40.0 
5 -1 -1 1 3.79 4.15 42.8 32.4 22.6 17.5 
6 1 -1 1 9.61 9.56 51.3 45.3 14.5 15.9 
7 -1 1 1 6.06 7.04 38.2 48.8 32.1 31.9 
8 1 1 1 14.5 14.3 43.5 61.7 25.5 28.2 
9 0 0 0 6.06 6.23 43.9 40.3 27.3 28.1 
10 0 0 0 6.49 6.23 49.8 40.3 35.8 28.1 
11 0 0 0 6.19 6.23 43.7 40.3 27.0 28.1 
12 0 0 0 6.21 6.23 40.3 40.3 30.8 28.1 
13 -1.63 0 0 2.49 1.64 27.1 29.8 11.8 18.1 
14 1.63 0 0 7.58 8.67 47.1 50.8 41.0 36.2 
15 0 -1.63 0 2.03 2.45 4.3 26.9 0 4.93 
16 0 1.63 0 8.02 7.85 58.0 53.7 33.4 30.4 
17 0 0 -1.63 2.28 3.28 28.5 29.3 15.8 17.1 
18 0 0 1.63 13.0 12.31 59.8 51.3 24.9 25.0 
19 0 0 0 6.1 6.23 45.6 40.3 23.9 28.1 
20 0 0 0 6.39 6.23 45.1 40.3 24.5 28.1 
*Refer to Table 2.4 for natural levels of variables 
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Figure 2.8. RSM plots representing the effect of temperature, time, and enzyme to 
substrate ratio (E:S) on the DH using Alcalase. Each plot shows the effect of two 
variables while the other variable is held constant. Enzyme.log 2 represents the 
transformation of the levels of E:S to the log base 2 scale used to create equal 
numerical movement from the 0 point to the ±1 levels.  
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2.5.2 Response Surface Modeling for % Reduction in Immunoreactivity per Each 
Sera Used  
 
For the sera from patient 3, the lack of fit p-value for a first order response was 
found to be significant as well as the lack of fit values for first order with two way 
interaction and the second order models, so model selection could not be based on this 
alone (Table 2.10). Analysis of the sequential model sum of squares p-values 
indicated that significant (P ≤ 0.05) model terms were only present in the linear model 
and that in higher order models the additional terms were not significant (Table 5.5 
Appendix F). In the linear model, all model terms were significant (time, temperature, 
and E:S). Although, this model had the lowest adjusted R
2 
(0.5034) in comparison to 
the other models, the significant model sum of square p-value for the linear model 
implied that the model is appropriately fit (Table 2.10). Thus, time, temperature, and 
E:S ratio all had significant effect on the % reduction in immunoreactivity (Figure 
2.9). Table 2.11 contains the actual and predicted responses for the model.  
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Figure 2.9. RSM plots representing the effect of temperature, time, and enzyme to substrate 
ratio (E:S) on the % reduction in immunoreactivity using sera from patient 3. Each plot 
shows the effect of two variables while the other variable is held constant. Enzyme.log 2 
represents the transformation of the levels of E:S to the log base 2 scale used to create 
equal numerical movement from the 0 point to the ±1 levels.  
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When fitting response models obtained using the sera from patient 6, all models 
including first order, first order with interaction, and second order were found to have an 
insignificant lack of fit (Table 2.10). Thus, further analysis was required in order to select 
the appropriate fit. Analysis of the sequential model sum of squares showed that the 
second order model was the best model with several model terms being significant (Table 
5.7 Appendix F). Temperature, time, temperature and E:S interaction, time squared, and 
E:S squared were all found to be significant. The second order model also had the best 
adjusted R
2 
at 0.7857. Thus, responses using sera from patient 6 were fit as a second 
order model (Table 2.9) and RSM plots were generated (Figure 2.10). Since the fit was a 
second order model, prediction of the levels of the different hydrolysis conditions that 
result in a maximum reduction in allergenicity were possible. Strong curvature is found in 
a second order model, allowing for the determination of a maximum response. Based on 
model selection and regression analysis, the conditions that would yield the greatest 
reduction in immunoreactivity, while the % DH does not exceed 8%, are time of 65 
minutes, temperature of 65°C, and an E:S of 0.1 mL of enzyme: 100 g protein. Table 2.10 
contains the actual and predicted responses for the model fit.  
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Figure 2.10 RSM plots representing the effect of temperature, time, and enzyme to 
substrate ratio (E:S) on the % reduction in immunoreactivity using sera from patient 6 
(soy specific IgE of 20.90 kU/L). Each plot shows the effect of two variables while the 
other variable is held constant. Enzyme.log 2 represents the transformation of the levels 
of E:S to the log base 2 scale used to create equal numerical movement from the 0 point 
to the ±1 levels.  
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Data obtained using sera from patient 7 was also fit as a second order model (Table 
2.9) and RSM plots were generated according to accordingly (Figure 2.11). All models 
showed insignificant lack of fit p-value (Table 2.10). Thus, further analysis was needed to 
select the appropriate model. The second order model was found to be the highest order 
polynomial with several model terms being significant based on the sequential model 
sums of square p-value (P ≤ 0.05) (Table 5.9 Appendix E). Temperature, time, E:S, 
temperature and E:S interaction, time and E:S interaction, time squared and E:S squared 
were all significant. This model also had the highest adjusted R
2
. Since data obtained 
using sera from patient 7 was fit as a second order model, conditions that yield the 
greatest reduction in immunoreactivity could be determined. The conditions that yield the 
greatest reduction in immunoreactivity while maintaining a DH of 8% were a time of 65 
minutes, temperature of 65°C and an E:S of 0.14 mL of enzyme to 100 g protein. Table 
2.12 contains the actual and predicted responses for the model fit.  
Similarly when fitting data obtained using sera from patient 9, all lack of fit p-values 
were not significant so further analysis was required to select a model. Analysis of the 
sequential p-value showed that the linear model was the highest order model with several 
model terms being significant (Table 5.11 Appendix E). Although the adjusted R
2 
was not 
the highest, significant terms included in the model were temperature and E:S (Figure 
2.12). Since the data obtained fit a linear model (Figure 2.12), conclusions can only be 
drawn about the % reduction in immunoreactivity within the levels that were tested. The 
% reduction in immunoreactivity continued to increase linearly with the increase in the 
levels of each factor. Consequently, optimum conditions that elicit the maximum 
response probably lies outside of the levels tested. Therefore, maximum reduction in 
allergenicity could not be detected for this set of data. For future work, more levels 
should be tested. Table 2.12 contains the actual and predicted responses for the model fit.  
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Table 2.12. Actual (A) and predicted (P) responses for the 20 hydrolysates obtained using 
Alkalize for the response variable DH, % reduction in immunoreactivity from serum 7, % 
reduction in immunoreactivity from sera 9, and % reduction in immunoreactivity from 
sera from patient 12. 
Run       Coded Levels* 
  
  
Sera from patient 7 Sera from patient 9 Sera from patient 12 
       x1        x2       x3         A                   P            A                  P            A                P 
1 -1 -1 -1 8.74 5.79 0.491 3.79 0 4.59 
2 1 -1 -1 22.1 24.1 23.9 19.5 17.8 15.8 
3 -1 1 -1 21.9 28.6 12.0 11.9 16.6 21.0 
4 1 1 -1 55.8 56.2 37.8 27.7 38.1 32.2 
5 -1 -1 1 37.7 40.4 21.9 16.3 20.3 12.7 
6 1 -1 1 55.6 38.7 43.5 32.0 22.1 23.9 
7 -1 1 1 22.1 46.0 21.4 24.4 32.4 29.1 
8 1 1 1 47.4 53.0 24.0 40.2 23.1 40.3 
9 0 0 0 47.0 45.4 16.9 22.0 26.2 22.4 
10 0 0 0 41.0 45.4 17.4 22.0 17.4 22.4 
11 0 0 0 49.8 45.4 25.1 22.0 25.0 22.4 
12 0 0 0 45.3 45.4 25.2 22.0 24.0 22.4 
13 -1.63 0 0 19.0 30.4 4.93 9.17 7.01 13.3 
14 1.63 0 0 47.9 51.4 24.4 34.8 33.3 31.6 
15 0 -1.63 0 19.0 21.6 10.0 15.3 0 9.08 
16 0 1.63 0 45.4 52.3 40.2 28.6 36.3 35.8 
17 0 0 -1.63 38.0 22.1 8.83 11.8 13.1 15.8 
18 0 0 1.63 50.4 48.1 37.1 32.0 30.5 29.0 
19 0 0 0 39.1 45.4 26.2 22.0 27.0 22.4 
20 0 0 0 48.4 45.4 18.4 22.0 38.3 22.4 
*Refer to Table 2.4 for natural levels of variables 
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Figure 2.11. RSM plots representing the effect of temperature, time, and enzyme to 
substrate ratio (E:S) on the % reduction in immunoreactivity using sera from patient 7 
(soy specific IgE of 4.16 kU/L). Each plot shows the effect of two variables while the 
other variable is held constant. Enzyme.log 2 represents the transformation of the levels 
of E:S to the log base 2 scale used to create equal numerical movement from the 0 point 
to the ±1 levels. 
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Figure 2.12. RSM plots representing the effect of temperature, time, and enzyme to 
substrate ratio (E:S) on the % reduction in immunoreactivity using sera from patient 9 
(soy specific IgE of 6.96 kU/L). Each plot shows the effect of two variables while the 
other variable is held constant. Enzyme.log 2 represents the transformation of the levels 
of E:S to the log base 2 scale used to create equal numerical movement from the 0 point 
to the ±1 levels.  
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Once again, when analyzing the data obtained using the sera from patient 12, all lack 
of fit p-values were found to be non-significant so further analysis was required (Table 
2.10). Analysis of the sequential model p-value (P ≤ 0.05) indicated that the linear model 
had the greatest number of significant model terms including time and temperature (Table 
5.13 Appendix E). Although the linear model only had an R
2 
of 0.5601, significance of 
model terms confirmed that the model was appropriately fit, and hence this mode was 
used to generate the RSM plots (Figure 2.13). Conclusions again can only be drawn about 
the % reduction within the levels that were tested. The % reduction in immunoreactivity 
increased linearly with higher levels of each factor. Conditions that lead to the greatest 
reduction in immunoreactivity probably lie outside of the parameters tested. Thus, more 
levels of the factors should be explored in future work. The conditions that yield that 
greatest reduction in immunoreactivity cannot be determined from this set of data. Table 
2.12 contains the actual and predicted responses for the model fit.  
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Figure 2.13 RSM plots representing the effect of temperature, time, and enzyme to 
substrate ratio (E:S) on the % reduction in immunoreactivity using sera from patient 12 
(soy specific IgE 45.30 kU/L). Each plot shows the effect of two variables while the other 
variable is held constant. Enzyme.log 2 represents the transformation of the levels of E:S 
to the log base 2 scale used to create equal numerical movement from the 0 point to the 
±1 levels.  
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2.6 Optimization of Hydrolysis Conditions to Result in the Greatest % Reduction in 
Immunoreactivity Across All Sera Used 
 
Analysis was conducted considering the % reduction in immunoreactivity obtained 
using the collected sera individually in order to take into account variation among sera. 
For the data that fit a linear model (obtained using sera from patient 3, 9, and 12) 
conclusions could only be drawn about the direction of movement and the expected % 
reduction in immunoreactivity. Within the bounds tested it can be concluded that the % 
reduction in immunoreactivity increased as the % DH increased when using sera from 
patients 3, 9, and 12. For the data that fit a second order model (obtained using sera from 
patient 6 and 7), the level of each variable that will result in the greatest reduction in 
immunoreactivity can be determined as curvature existed in the data. When the DH 
exceeds 8%, the protein functionality can be negatively affected and bitter peptides can 
be released. Thus, in order to produce a soy protein ingredient with reduced allergenicity 
and acceptable functionality and flavor, the DH must not exceed 8%. Thus, constraints 
were added to ensure that the DH did not exceed 8%.  
Constraint optimization is based on modifications to the model fit analysis. The path 
of steepest ascent is a mathematical parameter that aids in the determination of the 
direction of where the maximum response lies relative to the design center point. A 
modified path is created representing a direction vector that complies with the imposed 
constraint, but still targets a maximum response. The modified path direction vector is 
represented by: bi-dci with bi representing the linear path of a variable, c representing the 
constrained path of the variable, and d representing the regression slope, determined by 
Eq. 2.7. 
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Eq. 2.7 
 
An example of a modified path is shown in Figure 2.14.  
 
A modified path was determined for the data obtained using the different sera with 
constraints added on the levels of each experimental variable that would cause the % DH 
to exceed 8%. Hydrolysis conditions that resulted in the maximum % reduction in 
immnoreactivity with a DH of 7.5% using the different sera are predicted in Table 2.13. 
The hydrolysis conditions that resulted in the maximum % reduction were the same for 
all sera used with one exception. For the sera from patient 6, the E:S that elicited 
maximum response was slightly lower than that of the sera from patients 3, 7, 9 and 12. 
Therefore, the conditions that resulted in the maximum % reduction using sera from 
patients 3, 7, 9, and 12 were considered as the optimized hydrolysis condition.  
 
 
 
 
Figure 2.14. Example of a modified path created by constraints added to the response 
for a two variable experiment as denoted by x1 and x2. 
 
Unconstrained path 
Modified path
x2
x1
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Table 2.13. Optimized hydrolysis condition for different sera with constraints added onto 
the % DH. Data is presented in both the coded and natural level with X1 representing 
temperature, X2 representing time and X3 representing enzyme to substrate ratio (E:S). 
Sera  Hydrolysis Condition Coded level Natural Level  
3, 7, 9, 12 Temperature (°C), x1 1 65 
 Time (minutes), x2 1 65 
 E:S (mL:100g), x3 -0.60 0.12 
6 Temperature (°C), x1 1 65 
 Time (minutes), x2 1 65 
 E:S (mL:100g), x3 -1 0.1 
 
 
Once the optimized hydrolysis conditions were determined, ELISA’s were 
conducted to compare the actual % reduction in immunoreactivity to the predicted % 
reduction in immunoreactivity. Some variation did exist between the predicted and 
actual response at the optimized hydrolysis condition. The variation may be the result 
of a low adjusted R
2
, which was
 
found for the initial model fitting. The higher the 
adjusted R
2
, the better the selected model fits the data. Under optimal hydrolysis 
conditions, the actual DH was 7.8% while the predicted DH was 7.5% (Table 2.14), 
obtained using the model with an adjusted R
2
 of 0.9454. For the % reduction in 
immunoreactivity, the model that fit the data obtained using the sera from patient 7 had 
the highest adjusted R
2
. However, the predicted % reduction in immunoreactivity was 
58.18% while the actual % reduction was 44.57%. Interestingly, the sera from patient 3 
had the lowest adjusted R
2 
(0.5034), yet the actual % reduction in immunoreactivity 
was very close to the predicted value (Table 2.14). 
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Table 2.14 Actual and predicted % reduction in immunoreactivity of soy protein and 
DH produced under the optimized hydrolysis conditions of time = 65 minutes, 
temperature = 65°C, and enzyme to substrate ratio (E:S) = 0.12 mL enzyme : 100 g 
protein.  
 % Reduction in immunoreactivity DH 
 Sera  
   
 patient 3  Patient 6 
  
patient 7 patient 9  patient 12   
Actual  52.453% 19.787% 44.658% 43.036% 49.808% 7.81% 
Predicted  50.9782 % 40.0772% 58.1894% 30.229% 33.8843% 7.50% 
 
 
 
A possible explanation for the variation between the expected and predicted 
responses could be attributed to protein conformation. After hydrolysis the 
conformation of a protein is altered, which may expose or hide epitopes. The 
conformation of a protein can be further altered by attachment to the polystyrene well 
of the microtiter plate, further affecting the exposure of epitopes. To prevent this effect, 
denaturing agents such as SDS and β-mercaptoethanol can be added to eliminate 
protein folding by breaking hydrophobic interactions and disulfide linkages 
respectively. However, unfolding of the protein in such a manner will obscure the 
assessment of potential conformational epitopes.  
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2.7 Conclusions 
 
The allergenicity of SPI was reduced upon hydrolysis, but only up to a certain extent. 
Using serum from the patient with the highest soy specific IgE level (45.30 kU/L), the 
greatest % reduction in immunoreactivity was 38.12%. The utilization of RSM allowed 
for the determination of an optimized hydrolysis conditions that would result in the 
greatest % reduction in immunoreactivity for each sera used, while maintaining a DH < 
8%. Results for this work demonstrated that substantial reductions in allergenicity can be 
achieved at DH that would not adversely affect flavor and functionality. Functionality 
testing, namely emulsification capacity and gelation properties, as well as sensory 
evaluation of the modified soy protein are a natural follow up to this work. 
The next phase of this project will be to assess the impact of Maillard-induced 
glycosylation will have on the allergenicity of SPH. Regardless of the DH, 
immunoreactivity was still observed. A second technique, such as controlled Maillard-
induced glycosylation is needed to further reduce the allergenicity of soy protein and 
produce a hypoallergenic soy protein ingredient with acceptable flavor and functionality.  
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3. EFFECT OF LIMITED AND CONTROLLED MAILLARD-INDUCED 
GLYCOSYLATION ON THE ALLERGENICITY OF SOY PROTEIN 
HYDROLYSATE (SPH) 
 
3.1. Overview 
 
In an attempt to further reduce the allergenicity of soy protein subjected to limited 
hydrolysis, controlled Maillard-induced glycosylation was utilized. Conditions used for 
Maillard-induced glycosylation were carefully selected to ensure minimal, if any, 
propagation of the reaction to advanced stages. Amadori compound formation, monitored 
at 304 nm, was confirmed after 24 hours of incubation of SPH with dextran at 0.49 aw 
and 60°C. No browning was detected and only a 1.5% increase in fluorescence was 
observed even after 120 h of incubation of SPH with dextran confirming limited if any 
propagation to the intermediate and advanced stages of the Maillard reaction. Significant 
reductions (P ≤ 0.05) in immunoreactivity (up to 80%) were observed upon glycosylation 
of SPH compared to non-modified soy protein isolate. The greatest reduction in 
immunoreactivity (~80%) was observed when the serum from the patient with highest 
soy specific IgE was used (45.30 kU/L). Results from this work proved for the first time 
that the combination of limited enzymatic hydrolysis and controlled Maillard 
glycosylation has a great potential to substantially reduce the allergenicity of soy protein. 
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3.2. Introduction  
The use of soy protein ingredients is expected to increase globally due to their 
nutritional and functional characteristics, and to the changing consumer preference 
toward more economical protein sources. The greatest drawback, however, to the 
continued increase in the usage of soy protein is its allergenicity.  In the U.S., the number 
of individuals with food allergies is around 15 million, approximately 8% of the children 
and 4% of the adults (Branum et al., 2008; Food Allergy Research and Education, 2013). 
Soy protein has been declared by the Food and Drug Administration (FDA) as one of the 
“Big Eight” food allergens that are responsible for 90% of allergic reactions seen in 
adults and children. People in the US with allergies to soy represent 0.5% of the 
population (Sicherer et al., 2006). Therefore, protein modification techniques aimed at 
reducing or eliminating the allergenicity of soy protein is needed in order to prevent a 
decrease in the usage of soy protein ingredients. 
Among the current protein modification approaches to reduce the allergenicity of soy 
protein is Maillard-induced glycosylation (L’Hocine and Boyce, 2007). The allergenicity 
of soy protein, namely that of the Gly m Bd 30 has been reduced following Maillard-
induced glycosylation (Babiker et al., 1998; Usui et al,. 2004). The potential, however, of 
the Maillard reaction to reduce the allergenicity of a protein is complex. If the reaction is 
allowed to progress to the advanced stage, new epitopes, regions on the protein that can 
bind IgE and thus elicit an immune response, may be formed as a result of protein 
crosslinking (Maleki et al., 2000; Pastorello et al., 2002), making the protein more 
allergenic. 
The Maillard reaction consists of three distinct stages. In the initial stage, 
condensation occurs between the carbonyl group of a reducing sugar and an amine group 
of a protein to yield the Amadori product. The intermediate stage is classified by the 
breakdown of the Amadori product to give rise to many different intermediates formed 
by enolization, oxidation, dehydration, or cyclization reactions. The final stage is 
characterized by the formation of melanodins and other advanced glycation end products 
(AGEs), which have negative health consequences (Poulsen et al., 2013). 
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When the reaction progresses to the final stage, loss in nutrition and functional properties 
occur, limiting the potential food applications of the modified ingredient. In order to 
reduce allergenicity without inducing negative side effects, the Maillard reaction must, 
therefore, be limited to the early stages.  
The reduction of protein allergenicity following Maillard-induced glycosylation is 
dependent on several different factors including heating conditions, pH, water activity 
(aw), the type of sugar used, and the protein to sugar ratio. To target the early stage of the 
Maillard-reaction, a neutral pH, incubation temperature below 65°C and a aw in the range 
of 0.3-0.5 has been used (Mitchell, 1988).  The type of reducing sugar will have a 
significant effect on limiting the Maillard reaction to the early stages. The rate of the 
Maillard reaction progresses much quicker when a simple sugar such as glucose, with a 
high reducing power and dextrose equivalent is used as compared to a disaccharide or 
polysaccharide. Polysaccharides have a relatively low DE and reducing power.  
Additionally, the covalent attachment of polysaccharides creates steric hinderance 
preventing further glycosylation. Thus, the combination of low reducing power and steric 
hinderance allows the rate of the Maillard reaction to be better controlled. Current sugars 
that have been used for the glycosylation of soy protein include fructose, galactomannan, 
chitosan, and fructoligosaccharides (Babiker et al., 1998; Usui et al., 2004; van de 
Lagemaat, 2007). 
Different conditions have been tested to reduce the allergenicty of soy protein. For 
example, Usui et al. (2004) used chitosan, a temperature of 60°C, and 0.65 aw and 
incubation for 14 days while van de Lagemaat et al., (2007) utilized 
fructologiosaccharides, a temperature of 60°C, 0.65 aw and incubation for 19 days. While 
significant reductions in the allergenicity were achieved, little data however was provided 
to characterize the modified ingredient. Long incubation times can result in quality issues 
due to the propagation to the advanced stages of the Maillard reaction. Additionally, long 
incubation times (> 2 weeks) are not industry feasible.  
Limited glycosylation, however, might not be sufficient to eliminate allergenicity of 
soy protein. Thus, we need to explore a combination of methods. We have previously 
shown that limited enzymatic hydrolysis can be optimized to reduce allergenicity 
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(Chapter 2). Soy protein was hydrolyzed under the optimized hydrolysis conditions to 
produce SPH with a DH of 7.5% and ~50% reduction in allergenicity. It is hypothesized 
that limited and controlled Maillard-induced glycosylation can further reduce the 
allergenicity of the produced SPH by limiting the reactivity of the remaining epitopes and 
those exposed upon hydrolysis. Therefore, the objective of this work is to determine the 
effect of limited and controlled Maillard-induced glycosylation on the allergenicity of 
SPH produced under optimized conditions from objective 1. 
 
 
3.3 Materials and Methods  
 
3.3.1 Materials  
 
Defatted and minimally heat treated soy flour was generously provided by ADM 
(Decatur, IL). Food grade Alcalase 2.4L (2.4 AU-A/g) was kindly provided by 
Novozymes (Denmark). Pre-stained broad-range molecular weight standard (161-0318), 
Laemmli sample buffer (161-0737), 10X Tris/Glycine/SDS running buffer (161-0732), 
Mini-Protean TGX Precast Gels 4-20% (456-1093) were purchased from BioRad 
(Hercules, CA). Mouse Anti-Human IgE Fc (Biotin) was purchased from Abcam 
(ab99807) (Cambridge, England). Polyvinyl difluoride membrane (0.2 μm) was purchase 
from Millpore (Tewksbury, MA). Enhanced chemiluminescent substrate (PI32106) was 
obtained from Pierce (Rockford, IL). Goat anti-human IgE (16-10-04) was purchased 
from Kirkland and Perry Laboratories (Gaithersburg, Maryland). Streptavidin alkaline 
phosphatase (S2890), p-nitrophenol phosphate (N7653), streptavidin peroxidase (S5512), 
dextran (s2890) and OPA reagent (P1378) were purchased from Sigma-Aldrich (St. 
Louis, Mo). Polystrene (3370), UV 96 well (3635) and black 96 well (3916) microplates 
were purchased from Corning (Tewksbury, MA). Bicinchoninic acid (BCA) protein assay 
kit (23235) was purchased from Pierce. Pronase (70426430) was purchased from Roche 
Diagnostics (Indianapolis, IN). All reagent grade chemicals were purchased from Fisher 
Scientific (Pittsburgh, PA). 
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3.3.2 Preparation of SPI 
 
Soy protein isolate was produced as outlined in Section 2.3.2 
 
3.3.3 Preparation of SPH 
 
Soy protein hydrolysate was produced under the optimized conditions determined 
using RSM (Chapter 2). The optimized hydrolysis conditions were pH = 7.5, time = 65 
minutes, temperature = 65°C, and enzyme to substrate ratio (E:S) of 0.12 mL enzyme : 
100 g protein. Hydrolysis was performed as outlined in Section 2.3.5. The DH of the 
produced was ~7.81% as calculated following the pH-stat method. 
 
3.3.4 Glycosylation of SPI and SPH 
 
Both SPI and SPH were subjected to Maillard-induced glycosylation under controlled 
conditions. Glycosylation of SPI was carried out to determine the effect of glycosylation 
on the allergenicity of intact protein. This information was used to assess whether or not 
controlled Maillard-induced glycosylation and limited hydrolysis have a synergistic 
effect on reducing the allergenicity of soy protein. Both SPI and SPH were mixed with 
dextran in 1:4 ratio (w/w), dissolved in a phosphate buffer (0.1 M, pH 7), and lyophilized. 
The lyophilized samples were incubated in triplicate, in a desiccator, at 0.49 aw (using 
saturated potassium carbonate) and 60°C for 24, 48, 72, 96, and 120 hours. Control SPI 
and SPH samples without dextran were incubated under the same conditions. For this 
work, dextran (10 kDa) was selected as the carbohydrate in order to control the reaction 
rate. The dextrose equivalent (DE) of the dextran used is 6-7. Dextran (10 kDa) was 
selected based on the previous work of Wang and Ismail (2012), who found that dextran 
(10 kDa) could be used for minimal glycosylation and to improve the functionality of a 
protein.  
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The aw was set below the optimum for the Maillard reaction at 0.49 in order to better 
control the reaction and avoid the propagation to the advanced stages (Ames, 1990; 
Jiménez-Castaño et al., 2007). The aw used was below the aw (0.60-0.85) where increases 
in browning and extensive lysine blockage commonly occur (Eichner and Karel, 1972; 
Jokinen et al., 1976; Lea and Hannan., 1949; Loncin et al., 1968). A protein to 
carbohydrate ratio of 1:4 was selected based on previous findings using dextran to 
promote Maillard-induced glycosylation, while limiting propagation to the advanced 
stages (Wang & Ismail, 2012). The incubation temperature of 60°C was selected to avoid 
protein denaturation. Samples were pulled out at different time intervals, analyzed for 
protein using a nitrogen analyzer (LECO, St. Joseph, MI) following the Dumas method 
(AOAC 990.03), and stored at -20°C for later analysis.  
 
3.3.5 Monitoring of Amadori Compounds and Browning 
 
 The difference UV absorption (DUV) of partially glycosylated samples was 
determined following the methods outlined by Zhu et al. (2008) and Jiménez-Castaño et 
al. (2007). Partially glycosylated soy protein (PGSP) and partially glycosylated SPH 
(PGPSH) samples as well as non-incubated controls were analyzed in triplicate. Each 
sample (amount equivalent to 0.02 g of protein) was dissolved in 1 mL DDW and 
centrifuged at 13,800 x g for 10 min. An aliquot (200 μL) of each supernatant was loaded 
into a UV microplate and the absorption was read at 304 nm with a microplate reader 
(Biotek, Winooski, VT). Absorption at 304nm was recorded against a control as an 
indication of Amadori compound formation. Absorption at 420 nm was also recorded to 
monitor browning.  
3.3.6 Loss of Free Amine Groups 
 
 Percent of free amino groups was determined following the o-phthaldialdehyde 
(OPA) method outlined by Goodno et al. (1981) and Rao et al. (2012) using lysine as a 
standard (200μg/mL-5μg/mL). The OPA reagent was prepared as follows: 3.810g of 
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sodium tetraborate decahydrate was dissolved in double distilled water (DDW) and 
adjusted to a pH of 9.65. SDS (0.5 g) was added followed by the addition of 0.080g of 
OPA dissolved in 4 mL of ethanol. β-mercaptoethanol (200 μL) was added and the 
solution was diluted to 100 mL using DDW. Samples were prepared in triplicate, by 
dissolving 0.01 g of sample in 1% SDS (w/v). All samples were centrifuged at 13,800 x g 
for 10 minutes. The supernatant from each control (SPI and SPH) was diluted 4x using 
1% SDS (w/v) prior to analysis. No further dilutions were necessary for the supernatant 
of the glycosyalated samples. Protein content of the supernatant was determined using the 
BCA kit following the manufacturer’s instructions. Aliquots (50 μL) of samples were 
added to a UV microplate followed by the addition of 200 μL of the OPA reagent. The 
absorbance was read at 340 nm on a microplate reader (Biotek, Winooski, VT) with a 
hold time of 2 minutes. Percent amine blockage was determined first by calculating the 
lysine concentration (μg/mL) according to the lysine standard curve (Figure 5.7 
Appendix G).  The % lysine was then corrected by dividing by the protein content 
(μg/mL) determined using the BCA assay standard curve (Figure 5.8 Appendix G). 
Percent free lysine remaining and % lysine blockage were calculated following Eq. 3.1 
and Eq. 3.2 
 
% free lysine remaining = 100 – ((% Corrected lysineSPI or SPH - % Corrected                                                    
                               lysineglycosylated)/ (% Corrected lysineSPI or SPH))* 100    Eq. 3.1 
 
In order to determine the % amine blockage the following equation was used:  
% lysine blockage = 100 - % free lysine remaining             Eq. 3.2 
 
A sample calculation is found in Appendix G.  
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3.3.7 Fluorescence Measurement  
The extent of fluorescence was determined following the method outlined by Rao et 
al. (2013), with modifications. A sample of either SPI, SPH, PGSP, or PGSPH equivalent 
to 0.01 g protein was dissolved in 1 mL of DDW. An aliquot (178 μL) of pronase (7.0 
U/mg) was added to each sample. The samples, prepared in triplicate, were stirred for 50 
minutes and then centrifuged at 13,800 x g for 15 minutes. A 1:1 dilution of supernatant 
and phosphate buffered saline (PBS) (20 mM phosphate, 15 mM NaCl, pH 7.0) was 
prepared. An aliquot (200μL) of each diluted sample was loaded onto a black microplate 
and read in a microplate reader (Biotek, Winooski, VT) at an excitation wavelength of 
360 nm and emission wavelength of 460 nm. A quinine sulfate solution (5 μg/mL) was 
prepared as the standard by dissolving 10 mg of quinine sulfate in 18 M H2SO4 followed 
by dilution with PBS. Fluorescence intensity was determined by dividing the 
fluorescence of the sample by the fluorescence of quinine sulfate standard.  
 
3.3.8 Western Blot and Enzyme Linked Immunosorbant Assay (ELISA) 
Western blot and ELISA were followed as outlined in Sections 2.3.7 and 2.3.8. 
The only change was in the type of gel that was used for the western blot. Mini-Protean 
TGX 4-20% gradient gels were used in place of the Criterion TGX 4-20% gradient gels. 
 
3.3.9 Statistical Analysis 
Analysis of variance (ANOVA) was conducted utilizing SPSS for Windows. When a 
factor or interaction was found significant (P ≤ 0.05), differences between means was 
determined using Tukey-Kramer multiple means comparison. ANOVA tables can be 
found in Appendix I.  
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3.4 Results and Discussion  
3.4.1 Protein Content and Profile Analysis of PGSP and PGSPH 
 
The protein content of glycosylated samples ranged from 16-18% (Table 3.1), which 
was expected for samples incubated with dextran at a 1:4 ratio. After glycosylation of SPI 
with dextran, the α, α’, and β of β-conglycinin shifted to a higher molecular weight 
distribution as indicated by the longitudinal smearing observed in lanes 3-7 of Figure 3.1. 
Diftis et al. (2006) who glycosylated SPI with dextran confirmed that the β-conglycinin 
subunit more readily participates in Maillard-induced glycosylation. The shift to a higher 
molecular weight distribution confirms the covalent attachment of dextran to the protein 
subunits. The wide spread of molecular weight is attributed to the heterogeneous 
distribution of glycosylated subunits, meaning that each subunit might have been 
glycosylated with one or a different number of dextran units. The intensity of the protein 
bands corresponding to the acidic and basic subunits of glycinin became fainter (Lane 3-
7) as compared to Lane 2 (Figure 3.1) indicating that a portion of the glycinin subunits as 
well got glycosylated and thus the bands shifted to a higher molecular weight distribution 
contributing further to the observed smearing.  
The α’ and α subunits of β-conglycinin were no longer detected while the β subunit 
was significantly reduced in SPH produced under the optimized hydrolysis conditions 
(Figure 3.1, Lane 8). After glycosylation of SPH for 48-120 hours, the β subunit was no 
longer detectable. Glycinin subunits, on the other hand, were still present, yet the 
corresponding bands appeared fainter than their counterparts in SPI (compare Lane 2 to 
Lane 8). Upon glycosylation of SPH for 48-120 hours, a visual decrease in the band 
intensity corresponding to the A3 acidic subunit was observed, coupled with apparent 
longitudinal smearing (Lanes 9-12). Change in the intensity of the glycinin basic subunit 
was not as pronounced as that of the acidic subunit. An increase in lower molecular 
weight peptides (<20 kDa) was observed for all SPH samples, glycosylated and non-
glycosylated (Figure 3.1). Presence of low molecular weight peptides is attributed to the 
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enzymatic breakdown of proteins, namely β-conglycinin subunits. The bands found 
around 27 kDa that were not present in SPI (Lane 1 as compared to Lane 8 Figure 3.1) 
are also most likely from the hydrolysis of β-conglycinin. Upon glycosylation of SPH for 
48-120 hours the bands around 27 kDa appeared much fainter suggesting that they were 
glycated (Lanes 9-12 Figure 3.1). 
 
Table 3.1. Protein content of soy protein isolate (SPI), partially glycosylated soy protein 
(PGSP), soy protein hydrolysate (SPH), and partially glycosylated soy protein 
hydrolysate (PGSPH) +/- Standard Deviation and % Free Amine.  
Sample  Protein Content +/- 
SD* 
% Free Amine +/-  
SD* 
SPI 91.8+/- 0.422 5.91 +/- 0.023 
PGSP 24 17.5 +/- 0.458 5.35 +/- 0.083 
PGSP 48  17.7 +/- 0.832 5.18 +/- 0.046 
PGSP 72  17.0 +/- 0.665 4.93 +/- 0.065 
PGSP 96 16.6 +/- 0.380 4.85 +/- 0.117 
PGSP 120 17.6 +/- 0.449 4.89 +/- 0.052 
SPH 91.5 +/- 0.567 12.1 +/- 0.118 
PGSPH 24 17.3 +/ 0.0536 9.28 +/- 0.029 
PGSPH 48 16.5 +/- 0.409 8.98 +/- 0.088 
PGSPH 72 17.9 +/- 0.664 9.98 +/- 0.055 
PGSPH 96 17.3 +/- 0.361 9.53 +/- 0.047 
PGSPH 120 18.0 +/- 0.634 9.36 +/- 0.095 
 *SD : Standard deviation  
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Figure 3.1 SDS-PAGE gel of modified protein. Lane 1: molecular weight marker; Lane 
2: soy protein isolate (SPI); Lane 3-7: partially glycosylated soy protein (PGSP) for 24, 
48, 72, 96, and 120 h; Lane 8: soy protein hydrolysate (SPH) produced under the 
optimized hydrolysis conditions of time = 65 minutes, temperature = 60°C, and enzyme 
to substrate ratio (E:S), 0.12 mL enzyme : 100 g protein; Lane 9-12: partially 
glycosylated SPH (PGSPH) for 48, 72, 96, and 120 h; A: α’ subunit of β-conglycinin (72 
kDa); B: α subunit of β-conglycinin (68 kDa); C: β subunit of β-conglycinin (48 kDa); D: 
A3 acidic subunit of glycinin (42 kDa); E: A1, A2, A4 acidic subunit of glycinin (33.6-
37); F: basic subunit of glycinin (20 kDa).  
 
3.4.2 Amadori Compound Formation  
 
The formation of the Schiff base, prior to the reconfiguration into the Amadori 
compound, is the first measureable product of the Maillard reaction that can be used to 
assess the extent of Maillard-induced glycosylation. At 60°C and 0.49 aw, a significant 
difference in absorbance at 304 nm was observed between the non-incubated control at 
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time point 0 and the incubated sample at time point 24 h for both PGSP and PGPSH 
(Figure 3.2 A and B) confirming that glycosylation had occurred. No significant 
differences were observed after the 24 h time point for both PGSPH and PGSP indicating 
the rate of the reaction was very slow. This observation confirmed that the conditions 
used were ideal for maintaining a slow reaction rate. Compared to other DUV results, as 
is the case of whey protein glycosylation (Zhu et al., 2008), our increase in absorbance at 
304 nm was modest. Additionally, the absorbance at 420 nm was maintained below 0.08 
even after 120 h of incubation (Figure 5.9 Appendix H), confirming the absence of brown 
pigment formation. A modest change in absorbance at 304 nm coupled with no observed 
browning confirmed that the Maillard reaction conditions resulted in limited 
glycosylation with no propagation to advanced stages. Minimal formation of the Amadori 
compound could have been the result of steric hindrance or slow progression to the 
intermediate and advanced stages. First, steric hinderance caused by the attachment of 
dextran could limit the extent of protein carbohydrate interaction by limiting the 
accessibility of amine groups especially from lysine (Choi et al., 2005). The attachment 
of a polysaccharide, such as dextran, can also prevent the progression of the Maillard 
reaction by imparting partial stability to the Amadori compound by preventing side 
reactions and excessive color development (Kato, 2002).  
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Figure 3.2. Amadori compound formation as determined by DUV at 304nm of A) partially glycosylated 
soy protein (PGSP): and soy protein isolate (SPI) control; B) partially glycosylated soy protein 
hydrolysate (PGSPH): and soy protein hydrolysate control (SPH):☐ incubated at 60°C for 0-120h at 0.49 
aw. Error bars represent standard errors. Different lower case letters above the shapes indicate significant 
differences between different time points for the glycosylated samples according to Tukey-Kramer multiple 
means comparison test (P ≤ 0.05); n=3. 
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3.4.3 Extent of Free Amine Blockage  
 
The extent of glycosylation of SPI and SPH with dextran was assessed further by 
determining the extent of amine blockage. The % free amine groups in SPI prior to 
glycosylation was 5.9% (Table 3.1) compared to the average value of 5.4% (van de 
Lagemaat et al., 2007). The % free amine groups in SPH prior to glycosylation was 
12.11%. The higher % free amine groups in SPH compared to SPI was expected due to 
peptide bond breakage upon hydrolysis causing the release of free amine groups. A 
significant drop in % free amine was noted for both SPH and SPI after 24 of incubation 
with dextran (Table 3.1). Percent amine blockage, however, was more pronounced for 
SPH (~22%) than SPI (~17%) (Figure 3.3). No significant differences in % amine 
blockage for SPH was observed among the samples incubated for various time points. 
This observation complements the DUV results that also showed no statistical difference 
in absorbance at 304 nm beyond 24 h of incubation.  This observation further confirms 
the slow rate of the reaction. On the other hand, a significant difference in % amine 
blockage was noted between the PGSP sample incubated for 24 and that incubated for 96 
hours. 
Differences in the % amine blockage between PGSP and PGSPH can be attributed to 
differences in reactivity of folded and unfolded protein structure. For example, α-caesin 
because of its open structure and readily reacted with polysaccharides, while a folded 
protein, such as lysozyme, demonstrated a slow reactivity toward polysaccharides due to 
lower levels of lysine residues present on the exterior of the protein (Kato, 2002). Upon 
hydrolysis of a globular protein, such as soy protein, tertiary structure is lost and more 
reactive groups as exposed. Additionally, compared to SPI, SPH had higher % free amine 
groups that can potentially be glycosylated.  
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Research on soy protein glycosylation is limited. Achouri et al. (2005) glycosylated 
the glycinin fraction of soy protein by incubating with glucose at 0.65 aw, 50°C, and 
protein to sugar ratio of 1:0.5. These conditions resulted in 22% amine blockage of 
glycinin after only 48 hours of incubation as compared to our findings of a 17% amine 
blockage for SPI after 120 hours of incubation.  Furthermore, Lagemaat et al. (2007) used 
fructoligosaccharides to glycosylate SPI at 0.65 aw, 60°C and a protein to carbohydrate 
ratio of 1:4. After incubation with fructooligosaccharides for 19 days, approximately 76% 
of free amine groups were blocked. Thus, we can conclude that our free amine blockage 
and resulting degree of glycation was minimal as compared to Maillard-induced 
glycosylation of soy protein conducted by other researchers. Glycinin, namely the basic 
subunit, has fewer lysine residues relative to β-conglycinin, so the reactivity of this 
fraction reported by other researchers suggests the utilization of conditions that promoted 
the propagation of the reaction.  
 
Figure 3.3. OPA Extent of Free Amine Blockage for PGSP; and PGSPH; incubated at 60°C, 
0.49 aw, protein to carbohydrate ratio of 1:4 for 0-120h. Different lower case letters indicate 
significant differences among PGSPH stored at different times points and different upper case 
letters indicate significant differences among PGSP stored at different time points. Tukey-
Kraemer multiple mean comparison (P ≤ 0.05); n=3. Error bars represent the standard errors. 
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3.4.4 Extent of fluorescence  
To further understand the progression of the Maillard reaction, the fluorescence index 
was evaluated. Significant differences in the fluorescence index (FI) were observed 
between the non-incubated control and PGSP incubated for 72, 96, 120 h (Figure 3.4). 
Significant differences were also observed between the non-incubated control and 
PGSPH incubated for 96 and 120 hours. The change in FI index was minimal, however, 
increasing by only 1.5% after 5 days for both PGSP and PGSPH confirming that the 
reaction was properly controlled and limited to the early stage of the Maillard reaction.  
The relationship between fluorescence and the formation of brown pigments is 
complex. However, under ideal conditions, as this experiment would be considered due 
to the neutral pH and presence of phosphate buffer, an increase in fluorescent compounds 
is observed prior to a dramatic increase in the formation of brown pigments (Friedman et 
al., 1950; Labuza, 1994; Overby et al., 1951). After Amadori rearrangement, small 
molecules form that have fluorescent capabilities (Burton et al., 1963). A significant 
increase in colorless intermediates will form as a result of chemical change (enolization, 
oxidation, dehydration, or cyclization reactions) to the molecules involved in the reaction 
before a notable production of brown pigments develop. These intermediate products can 
be used to detect the propagation of the reaction (Friedman et al., 1950; Karel et al., 
1964; Schnickels et al.,1976). It is important to recognize that advanced glycation 
endproducts formed during the advanced stage of the Maillard reaction can also fluoresce 
(Tessier et al., 2022). Since no visual changes in browning were observed, we can 
conclude that the observed fluorescence is attributed to the breakdown of the Amadori 
compound at the beginning of the intermediate stage and not a result of the formation of 
advanced glycation endproducts.   
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Figure 3.4. Fluorescence index of PGSP and PGSPH incubated with dextran at 60°C, 
0.49 aw for 0, 24, 48, 72, 96, 120. Error bars represent the standard errors. Different lower 
case letters indicate significant differences among PGSP samples, while different upper 
case letters indicate significant differences among PGSPH samples, according to Tukey-
Kramer multiple means comparison (P ≤ 0.05); n = 3. 
 
3.4.5 Effect of Controlled and Limited Glycosylation on the Immunoreactivity of 
SPI and SPH 
The immunoreactivity of the glycosylated samples was determined using human sera 
with varying soy specific IgE levels in order to understand the combined effect of limited 
hydrolysis and Maillard-induced glycosylation on the allergenicity of soy protein. Since 
no browning was observed and coupled with limited glycosylation of all incubated 
samples, coupled with no observed browning, Western blots were conducted on selected 
samples including PGSPH 72, 96, and 120 hours and PGSP 96 and 120 hours. Although 
the α’, α, and β of β-conglycinin appeared to have been glycosylated as discussed in 
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Section 3.3.1, immnoreactivity was still observed around 72 kDa (close to the molecular 
weight of the α’ and α subunits) for PGSP but was not as intense as that of SPI (Figure 
3.5). This observation was the same for different Western blots generated using different 
sera. However, the immunoreactivity shifted toward a higher molecular weight as noted 
by the longitudinal smearing, which indicated that even when glycosylated, the proteins 
remained immunoreactive. Similarly, the acidic and basic subunits of glycinin remained 
immunoreactive post glycosylation, with slight differences across the sera used.  
As discussed previously, Alcalase hydrolysis targeted mostly the α’, α, and β subunits 
of β-conglycinin and to a much lesser extent, the acidic and basic subunits of glycinin. 
Consequently, the immunoreactivity of β-conglycinin was not apparent in all the Western 
blots for SPH and PGSPH samples. The immunoreactivity of the acidic subunit of 
glycinin upon hydrolysis was significantly reduced (compared to SPI), and that of the 
basic subunit of glycinin was slightly reduced. The immunoreactivity of SPH shifted to 
the lower molecular weight region, indicating that the released peptides upon hydrolysis 
retained some of the linear epitopes, most noticeably for the Western blot developed 
using the sera from patient 12. Not much of a difference was noted in the 
immunoreactivity upon glycosylation of SPH. A slight reduction in the reactivity of the 
basic subunit was reduced in samples with longer glycosylation times. For the western 
blots developed using sera from patient 6, 7, and 9 (Figure 3.5), a slight immunoreactivity 
of the acidic subunit of glycinin could be observed, which was reduced even further upon 
glycosylation for longer incubation times. Glycinin has fewer reactive lysine residues, 
especially on the basic subunit (Utsumi et al., 1997), which may explain the minimal 
reduction in immunoreativity of the basic chain as this subunit had been minimally 
glycosylated if at all. 
Changes observed in the western blots may reflect changes in the conformation of the 
protein upon glycosylation, namely the acidic subunits of glycinin and the α’, α, and β 
subunits of β-conglycinin. Upon covalent attachment of a polysaccharide, the protein 
undergoes structural changes to the secondary and tertiary configuration, resulting in 
partial unfolding (Wang et al., 2013). Modifications to the protein structure, which result 
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in a change in protein conformation will affect the immunoreactivity either by exposing 
IgE binding epitopes or making them unaccessible for IgE binding.   
 
 
 
 
 
 
Figure 3.5. SDS-PAGE gel and corresponding Western blots developed using different human sera. Lane 1: 
molecular weight marker; Lane 2: soy protein hydrolysate (SPH) produced under the optimized hydrolysis 
conditions of time = 65 minutes, temperature = 60°C, and enzyme to substrate ratio (E:S), 0.12 mL enzyme 
: 100 g protein; Lane 3-5: partially glycosylated soy protein hydrolysate (PGSPH) for 72, 96, and 120 h; 
Lane 6: soy protein isolate (SPI); Lane 7-8: partially glycosylated soy protein (PGSP) for 96 and 120 h; A: 
α’ subunit of β-conglycinin (72 kDa); B: α subunit of β-conglycinin (68 kDa); C: β subunit of β-
conglycinin (48 kDa); D: A3 acidic subunit of glycinin (42 kDa); E: A1, A2, A4 acidic subunit of glycinin 
(33.6-37); F: basic subunit of glycinin (20 kDa).  
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An indirect ELISA was used to quantitatively assess the immunoreactivity of 
glycosylated protein samples. The extent of immunoreactivity of SPI, SPH, PGSP, and 
PGSPH varied among sera from different patients. For the most part, compared to SPI, 
SPH had a significantly (P ≤ 0.05) greater reduction in immunoreactivity than PGSP 96 
and PGSP 120 (Figure 3.6). The combined effect of limited hydrolysis and controlled 
Maillard-induced glycosylation was greater for samples glycosylated for longer periods 
of time, when the sera from patient 12 was used, leading to significant differences among 
SPH, PGSPH 96, PGPSH 120. Using sera from patient 12, the observed reduction in 
immunoreactivity of PGSPH 96 and PGSPH 120 was additive. A 28-42 % reduction in 
immunoreactivity was observed for PGSP 96 and PGSP 120 respectively, a 50 % 
reduction in immunoreactivity for SPH, and an 83 and 82 % reduction in 
immunoreactivity for PGPSH 96 and PGSPH 120 respectively. Sera from patient 12 had 
the highest soy specific IgE level. Variability in the immunoreactivity of sera with lower 
soy specific IgE levels for PGPSH 120 and PGSP 120 was observed when using sera 
from patient 7 (soy specific IgE 4.16 kU/L). The lower sensitivity of the sera from patient 
7 resulted in no significant reductions in the immunoreactivity for PGSPH 120 relative to 
SPH. Using other remaining sera resulted in mixed outcomes (Figure 5.10 Appendix J). 
The variability among sera needs to be addressed carefully when developing 
hypoallergenic proteins.  
The use of individual human sera as opposed to pooled human sera provides a better 
estimate of the degree of variability in IgE that can bind to different protein fractions. 
Song et al. (2008) utilized individual human plasma of varying IgE levels as well as 
pooled human sera. The authors concluded that the pooled human plasma demonstrated 
greater intensity in IgE binding in Western blots. The pooled human sera, however, did 
not adequately reflect changes in IgE binding observed among the most sensitive 
individuals, which, as observed in this work, are likely to be affected by minimal changes 
in protein conformation. 
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In order to assess the immunoreactivity of the modified protein, polyclonal antibodies 
were used in comparison to monoclonal antibodies. Usui et al. 2004 glycosylated soy 
protein with chitosan and evaluated the effect of glycosylation on the conformation of the 
protein and thus epitopes available for IgE binding using a monoclonal antibody 
specifically for P34. As seen in this work and confirmed by Difitis et al. (2006), 
glycosylation can occur on several different protein subunits present in soy protein, not 
just the P34 subunit. Thus, in order to assess the efficacy of protein modification, the use 
of polyclonal antibodies provides more inclusive information regarding all protein 
subunits. 
 
 
 
 
 
 
Figure 3.6. % Reduction in immunoreactivity of SPH, PGPSH, and PGSP relative to SPI using 
sera from patient 12 and 7. Error bars represent the standard errors. Different lower case letters 
indicate significant differences among PGSP 48-120h, SPH, and PGSPH 48-120h for patient 12 
sera, while different upper case letters indicate significant differences among PGSP 48-120h, 
SPH, and PGSPH 48-120h for patient 7 sera according to Tukey-Kramer multiple means 
comparison test (P<0.05); n=3. 
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3.5 Conclusions  
 
The findings from this work confirm that the Maillard-reaction was limited to the 
early stages as indicated by the extent of Amadori compound formation, fluorescence 
index, and free amine blockage. Comprehensive testing was conducted to evaluate the 
propagation of the Maillard reaction as compared to other researchers. This work 
provides, for the first time information about the combined effect of two different protein 
modification methods on the allergenicity of soy protein. Results proved that controlled 
Maillard-induced glycosylation can further reduce the immunoreactivity of a protein that 
has been previously subjected to limited enzymatic hydrolysis under optimized 
conditions. Structural modification may have occurred at regions that destroyed linear 
and/or conformational epitopes. The conditions utilized show promise, and should be 
further explored in order to determine industry feasibility. Additionally, glycosylation 
conditions need further optimization to ensure maximum reduction in immuoreactivity, 
regardless of the characteristics of the serum used. The synergistic effect of combined 
enzymatic hydrolysis and glycosylation modification on soy protein allergenicity has yet 
to be proved with additional research.   
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Chapter 4. Overall conclusions, implications, and recommendations 
 
The use of RSM was beneficial in understanding the effect of different enzymatic 
conditions on the DH and allergenicity of soy protein. It also provided optimized 
conditions that maintained a limited DH (7.5% DH) and resulted in substantial reductions 
(up to 50%) in the immunoreactivity of soy protein. Variability in the % reduction in 
immunoreactivity was observed among sera from different patients. This observation was 
attributed to different sensitivity to the simultaneous cleavage and exposure of IgE 
binding upon hydrolysis. The percent reduction in immunoreactivity of the SPH under 
optimized conditions ranged from 20-52%. Thus, a second technique, Maillard-induced 
glycosylation, was needed to further reduce the immunoreactivity of soy protein. The 
combination of two different protein modification techniques, which were limited and 
controlled, further reduced the immunoreactivity of soy protein to levels not achieved 
with a single protein modification technique, without jeopardizing the overall quality. 
Additionally, this work provided the Maillard-induced glycosylation conditions for soy 
protein that prevented the progression of the reaction to the advanced stages. Up to an 
80% reduction in immunoreactivity was achieved while maintaining the overall quality of 
the protein.  
Further optimization of Maillard-induced glycosylation conditions using RSM is 
suggested to achieve a greater reduction (> 90%) in immunoreactivity in order to be 
claimed as a hypoallergenic product. Results of this work revealed an additive effect 
rather than a synergistic effect. Further optimization of glycosylation conditions may 
result in a greater and more of a synergistic effect by blocking original and newly 
exposed epitopes upon hydrolysis. Additionally, optimization of Maillard-induced 
glycosylation conditions is necessary to result in significant reductions in 
immunoreactivity across different sera IgE levels. Epitope mapping can provide 
information about where glycosylation has occurred, which will provide information 
about how the location of the covalent attachment of a polysaccharide influences the 
immunoreactivity. Epitope mapping can also provide information on epitopes that got 
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hydrolyzed, exposed, or blocked. This information can be used to explain additive or 
synergistic effects of the combined methodologies.  
Although conditions utilized for both enzymatic hydrolysis and Maillard-induced 
glycosylation were carefully selected to avoid potential issues that arise such as bitter 
flavor generation, decreased digestibility, and excessive color development, the 
functionality of the protein must be investigated. As previously demonstrated by other 
researchers, both protein modification techniques can result in enhanced protein 
functionality when properly controlled. While the conditions chosen for this work can be 
industry feasible, scaling up work needs to be done to ensure cost effective approaches 
that minimize waste streams, excess enzyme, and free dextran in the final product.  
With further optimization of Maillard-induced glycosylation, testing of functionality, 
and industry feasible studies, in vivo testing of the hypoallergenic product would be a 
natural follow up investigation. In vivo testing will confirm the hypoallergenicity of the 
protein product and thus its safe applications in various food products. That said, the 
results obtained from this work, provide the necessary information and the premises for 
future studies intended to prove the potency of the combined methodologies to produce a 
hypoallergenic protein ingredient (not only soy protein), while maintaining functionality, 
flavor, and nutritional quality.  
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Appendix  A: Example Calculations for DH Determination  
 
 
DH = (h/htot) x 100 = [(B x Nb)/(MP x α x htot)]*100 
 
Where B is the volume of the NaOH necessary to keep the pH constant = 10.5mL 
  
Nb = Normality of the NaOH = 0.2N 
 
MP is the mass of the protein (g N x 6.25) = 7.5g 
 
htot = 7.75 meq/g (for soy protein) 
 
α is the degree of dissociation of the α-NH2 groups and is expressed as: 
 
    
 
α = 1/(1 + 10pK-pH) 
 
 
 
The pK value varies significantly with temperature and can be estimated as follows: 
 
 
     pK = 7.8 + (298-T)/(298 x T) x 2400 
 
 
where T is the absolute temperature (K).  
 
At 60°C, pK = 7.8 + [((298-(60 + 273)/298*(60 + 273))] = 6.95 
 
Therefore, at pH 7.5, α = 1/(1 + 106.95-7.5) = 0.78 
 
Finally, DH = ((10.5mL x 0.2 moles/L)/(7.5g x 0.78 x 7.75 meq/g)) x 100 = 4.63% 
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Appendix B: Example Calculation for % Reduction in Allergenicity  
 
 
% Reduction in allergenicity = (Corrected ABSSPI – Corrected ABSSPH/Corrected ABSSPI) 
                                                   x 100         
 
Where ABS is the absorbance at 405nm;  
Corrected ABSSPI  is equivalent to (ABSSPI positive control sera – ABS2nd antibody) =   
(0.902 – 0.089) 
Corrected ABSSPI is equivalent to (ABSSPH positive control sera – ABS2nd antibody) = 
(1.432 – 0.089) 
 
Therefore % reduction in allergenicity = (((1.432-0.089)(0.902-0.089))/(1.432-0.089)) x          
           x 100 = 81.3%  
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Appendix C: Western blots for Soy Protein Hydrolysate from RSM 
 
 
 
 
 
Figure 5.1 Western blots using different sera showing the immunoreactivity of SPI and 
SPH 1-15. The SPH numbering corresponds to those presented in Table 2.4. A)Western 
blot using sera from patient 12 (soy specific IgE 45.90 kU/L); B) Western blot using sera 
from patient 9 (6.96 kU/L soy specific IgE); A: α’ (72 kDa); B: α (68 kDa) of β-
conglycinin; C: β (48 kDa) from β-conglycinin; D: glycinin A3 acidic chain (42 kDa); E: 
glycinin A1, A2, A4 33.6-37.0 acidic chain; F: glycinin basic chain. 
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Figure 5.2 Western blots using different sera showing the immunoreactivity of SPI and 
SPH 1-15. The SPH numbering corresponds to those presented in Table 2.4. A)Western 
blot using sera from patient 12 (soy specific IgE 45.90 kU/L); B) Western blot using sera 
from patient  (4.16 kU/L soy specific IgE); A: α’ (72 kDa); B: α (68 kDa) of β-
conglycinin; C: β (48 kDa) from β-conglycinin; D: glycinin A3 acidic chain (42 kDa); E: 
glycinin A1, A2, A4 33.6-37.0 acidic chain; F: glycinin basic chain. 
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Figure 5.3 Western blots using different sera showing the immunoreactivity of SPI and 
SPH 1-15. The SPH numbering corresponds to those presented in Table 2.4. A)Western 
blot using sera from patient 3 (soy specific IgE 45.90 kU/L); B) Western blot using sera 
from patient  (5.67 kU/L soy specific IgE); A: α’ (72 kDa); B: α (68 kDa) of β-
conglycinin; C: β (48 kDa) from β-conglycinin; D: glycinin A3 acidic chain (42 kDa); E: 
glycinin A1, A2, A4 33.6-37.0 acidic chain; F: glycinin basic chain. 
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Appendix D: Reduction in allergenicity for patient ELISA data  
 
 
 
 
 
 
 
 
 
Figure 5.4. ELISA data collected for the % reduction in immunoreactivity using sera 
from patient 3 (soy specific IgE of 5.61 kU/L. Error bars indicate standard error. Means 
for each SPH that are statistically different share different letters while those that are not 
share the same letter as determined using Tukey-Kramer multiple means comparison test 
(P ≤ 0.05); n=3. 
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Figure 5.5. ELISA data collected for the % reduction in immunoreactivity using sera 
from patient 9 (soy specific IgE of 6.96 kU/L). Error bars indicate standard error. Means 
for each SPH that are statistically different share different letters while those that are not 
share the same letter as determined using Tukey-Kramer multiple means comparison test 
(P ≤ 0.05); n=3. 
 
 
 
 
 
 
 
 
 
0
10
20
30
40
50
60
SPH 1 SPH 2 SPH 3 SPH 4 SPH 5 SPH 6 SPH 7 SPH 8 SPH 9 SPH
10
SPH
11
SPH
12
SPH
13
SPH
14
SPH
15
%
 r
e
d
u
c
ti
o
n
  
in
 i
m
m
u
n
o
re
a
c
ti
v
it
y
a
s 
C
o
m
p
a
re
d
 t
o
 S
P
I
Hydrolysate 
a
ab
b
ab
bc
c
c
bc
c
d
c
d
d
d
c
  135 
 
 
 
Appendix E: Analysis of Variance for % reduction in immunoreactivity for SPH  
samples  
 
 
Table 5.1. Analysis of variance for different sera for the % reduction in immunoreactivity  
Sample 
Analysis 
Source of Variation Degree of 
Freedom 
Mean Squares Significance 
% reduction 3 SPH type  14 690.565 <0.0001 
 Error 23 18.901  
% reduction 6 SPH type  14 423.291 <0.0001 
 Error  21 29.286  
% reduction 7 SPH type  14 557.739 <0.0001 
 Error  26 15.072  
% reduction 9 SPH type  14 574.468 <0.001 
 Error  28 19.332  
% reduction 12 SPH type 14 691.508 0.019 
 Error 28 15.253  
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Appendix F: ANOVA for model fit and sequential sum of squares for RSM data 
 
Table 5.2. ANOVA for % DH second order response using Alcalase RSM data 
Source  SS
D 
DF
E 
MS
F 
F-Value P value > F 
Model 220.96 9 24.55 37.53 <0.0001 
A-A
A 61.98 1 61.98 94.74 <0.0001 
B-B
B 36.53 1 36.53 55.84 <0.0001 
C-C
C 102.17 1 102.17 156.16 <0.0001 
AB 1.85 1 1.85 2.83 0.1233 
BC 0.57 1 0.57 0.87 0.3738 
AC 8.38 1 8.38 12.52 0.0050 
A
2 2.12 1 2.12 3.25 0.1017 
B
2 2.16 1 2.16 3.31 0.0989 
C
2 4.57 1 4.57 6.98 0.0247 
Residual 6.54 10 0.65   
Lack of Fit  6.40 5 1.28   
Pure Error  0.140 5 0.028 45.60 0.004 
Total 227.50 19    
A
A: temperature; 
B
B: time; 
c
C: enzyme to substrate ratio; 
D
SS: sum of squares; 
E
DF: 
degrees of freedom; 
F
MS: mean squares  
 
Table 5.3. ANOVA for % DH sequential model sum of squares using Alcalase RSM data 
Source SS
D 
DF
E 
MS
F 
F-value P value > 
F 
FO
A
 vs. 
mean 
200.68 3 66.89 39.90 <0.0001 
FO vs. 
FO + 
2WI
B 
10.80 
 
3 3.60 2.92 0.0738 
FO +2WI 
vs. SO
C 
9.48 3 3.16 4.83 0.0250 
Residual  0.28 3 0.047   
A
FO: first order; 
B
FO + 2WI: first order plus two way interaction; 
c
SO: second order; 
D
SS: sum of squares; 
E
DF: degrees of freedom; 
F
MS: mean squares  
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Table 5.4. Analysis of Variance (ANOVA) of Linear Response for sera from patient 3  
Source  SS
D 
DF
E 
MS
F 
F-value  p-value  
Model  2064.07 3 688.02 7.47 0.0024 
A
A
  555.00 1 550.00 6.02 0.0259 
B
B 900.76 1 900.76 9.78 0.0065 
C
C 608.32 1 608.32 6.60 0.0206 
Residual  1474.08 16 92.32   
Lack of fit  1425.89 11 129.63 13.45 0.0050 
Pure Error  48.19 5 9.64   
A
A: temperature; 
B
B: time; 
c
C: enzyme to substrate ratio; 
D
SS: sum of squares; 
E
DF: 
degrees of freedom; 
F
MS: mean squares  
 
Table 5.5. Sequential Mean Squares for sera Patient 3  
Source  SS
D 
DF
E 
MS
F 
F-value p-value 
FO
A
 vs. 
mean 
2064.07 3 688.02 7.47 0.0024 
 
FO vs. FO + 
2WI
B 
394.61 3 131.54 1.58 0.2409 
 
SO
C
 vs. FO + 
2WI 
327.65 3 109.22 1.54 0.2856 
 
Residuals 67.32 6 11.22   
A
FO: first order; 
B
FO + 2WI: first order plus two way interaction; 
c
SO: second order; 
D
SS: sum of squares; 
E
DF: degrees of freedom; 
F
MS: mean squares  
 
Table 5.6. Analysis of Variance (ANOVA) for Second Order response for sera from 
Patient 6  
Source SS
D 
DF
E 
MS
F 
F-Value p-value 
Model 2030.44 9 225.60 8.74 0.0011 
A
A 408.73 1 408.73 15.83 0.0026 
B
B 850.82 1 850.82 32.96 0.0002 
C
C 78.14 1 78.14 3.03 0.1125 
AB 1.63 1 1.63 0.063 0.8065 
AC 386.31 1 386.61 14.96 0.0031 
BC 15.15 1 15.15 0.59 0.4614 
A
2 1.88 1 1.88 0.073 0.7928 
B
2 215.02 1 215.02 8.33 0.0162 
C
2 92.87 1 92.87 3.60 0.0871 
Residual  25.82 1 25.82   
Lack of Fit  32.01 10 32.01 1.63 0.3021 
Pure Error  19.62 5 19.62   
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A
A: temperature; 
B
B: time; 
c
C: enzyme to substrate ratio; 
D
SS: sum of squares; 
E
DF: 
degrees of freedom; 
F
MS: mean squares  
 
 
Table 5.7. Sequential mean squares for sera form patient 6 
Source  SS
D 
DF
E 
MS
F 
F-value  p-value  
FO
A
 vs. 
mean  
1337.68 3 445.89 7.50 0.0024 
FO vs. FO + 
2WI
B
  
403.09 3 134.36 3.19 0.0596 
SO
C
 vs. FO 
+ 2WI 
289.67 3 96.56 3.74 0.0490 
Residuals  102.82 6 17.14   
A
FO: first order; 
B
FO + 2WI: first order plus two way interaction; 
c
SO: second order; 
D
SS: sum of squares; 
E
DF: degrees of freedom; 
F
MS: mean squares  
 
 
 
Table 5.8. Analysis of Variance (ANOVA) for % reduction in immunoreactivity for 
second order response for sera from patient 7  
Source  SS
D 
DF
E 
MS
F 
F-value p-value  
Model  3305.96 9 367.33 12.66 0.0002 
A
A 556.39 1 556.39 19.17 0.0014 
B
B 1182.82 1 1182.82 40.75 <0.0001 
C
C 846.36 1 846.36 29.16 0.0003 
A:B 42.39 1 42.39 1.46 0.2546 
A:C 201.70 1 201.70 6.95 0.0249 
B:C 149.16 1 149.16 5.14 0.0468 
(A)
2 36.76 1 36.76 1.27 0.2867 
(B)
2 131.89 1 131.89 4.54 0.0588 
(C)
2
 196.61 1 196.61 6.77 0.0264 
Residual 290.24 1 29.02   
Lack of fit  201.10 10 40.22 2.26 0.1964 
Pure error  89.14 5 17.83   
A
A: temperature; 
B
B: time; 
c
C: enzyme to substrate ratio; 
D
SS: sum of squares; 
E
DF: 
degrees of freedom; 
F
MS: mean squares  
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Table 5.9. Sequential Model Sum of Squares for sera from Patient 7  
Source  SS
D 
DF
E 
MS
F 
F-value  p-value  
FO
A
 vs. mean  2585.57 3 861.86 13.64 0.001 
FO vs. FO + 
2WI
B 
393.26 3 131.09 2.76 0.0845 
SO
C
 vs. FO + 
2WI 
327.13 3 109.04 3.76 0.0484 
Residual  142.61 6 23.77   
A
FO: first order; 
B
FO + 2WI: first order plus two way interaction; 
c
SO: second order; 
D
SS: sum of squares; 
E
DF: degrees of freedom; 
F
MS: mean squares  
 
Table 5.10. Analysis of Variance (ANOVA) for Linear Response Model for sera from 
patient 9 
Source  SS
D 
DF
E 
MS
F 
F-value  p-value  
Model  1568.07 3 522.69 8.57 0.0013 
A
A 825.51 1 825.51 13.53 0.0020 
B
B 221.57 1 221.57 3.63 0.0748 
C
C 520.98 1 520.98 8.54 0.0100 
Residual  976.09 16 61.01   
Lack of fit  879.06 11 79.98 4.15 0.0641 
Pure error  96.33 5 19.27   
A
A: temperature; 
B
B: time; 
c
C: enzyme to substrate ratio; 
D
SS: sum of squares; 
E
DF: 
degrees of freedom; 
F
MS: mean squares  
 
 
 
Table 5.11. Sequential Model Sum of Squares for sera from Patient 9 
Source  SS
D 
DF
E 
MS
F 
F-value  p-value  
FO
A
 vs. 
mean 
1568.07 3 522.69 8.57 0.0013 
FO vs. FO + 
2WI
B 
363.99 3 121.33 2.58 0.0986 
SO
C
 vs. FO 
+ TWI 
124.57 3 41.52 0.85 0.4969 
 
Residual  111.29 6 18.55   
A
FO: first order; 
B
FO + 2WI: first order plus two way interaction; 
c
SO: second order; 
D
SS: sum of squares; 
E
DF: degrees of freedom; 
F
MS: mean squares  
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Table 5.12. Analysis of Variance (ANOVA) for first order response for sera from Patient 
12   
Source  SS
D 
DF
E 
MS
F 
F-value P-value  
Model  1536.65 3 512.22 9.06 0.0010 
A
A 419.70 1 419.70 7.43 0.0150 
B
B
  898.44 1 898.44 15.90 0.0011 
C
C 218.50 1 218.50 3.87 0.0668 
Residual  904.14 16 56.51   
Lack of fit  673.72 11 61.25 1.33 0.3968 
Pure Error  230.42 5 46.08   
A
A: temperature; 
B
B: time; 
c
C: enzyme to substrate ratio; 
D
SS: sum of squares; 
E
DF: 
degrees of freedom; 
F
MS: mean squares  
 
Table 5.13. Sequential Model Sum of Squares for  sera from Patient 12  
Source  SS
D 
DF
E 
MS
F 
F-value  p-value  
FO
A
 vs. 
mean 
1536.65 3 512.22 9.06 0.0010 
FO vs. FO + 
2WI
B
  
351.59 
 
3 117.20 2.76 0.0847 
SO
C
 vs. FO 
+TWI 
137.01 3 45.67 1.10 0.3942 
Residual 243.36 6 40.56 
 
1.06  
A
FO: first order; 
B
FO + 2WI: first order plus two way interaction; 
c
SO: second order; 
D
SS: sum of squares; 
E
DF: degrees of freedom; 
F
MS: mean squares  
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APPENDIX G: Example calculation for determination of % lysine blockage 
 
The % amine blockage is determined using the following steps: 
 
Lysine concentration is determined from the lysine standard curve 
 
y = 0.0101x + 0.0476 with y representing the absorbance at 340 nm and x the       
lysine concentration in μg/mL 
 
0.981 – 0.0476 / (0.0101) = 92.42 μg/mL lysine for SPI 
 
 
 
 
 
 
Figure 5.6. Example standard curve using lysine as standard  
 
 
 
The % lysine corrected is determined first by determining the protein content of the 
sample using the BCA assay standard curve  
 
y = 0.001x + 0.2119 with y representing the absorbance at 562 nm and x  
representing the protein concentration in μg/mL 
 
 
 
 
 
 
 
 
 
y = 0.0101x + 0.0476
R² = 0.996
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Figure 5.7. BCA standard curve using bovine serum albumin as  (BSA) the standard 
 
 
1.784 - 0.2119 / (0.001) = 1561.8 μg/mL protein for SPI 
 
% corrected lysine = (lysine concentration (μg/mL) / protein concentration       
(μg/mL))*100 
 
                              = (92.42 / 1561. 8) * 100 
 
                              = 5.91 % 
 
The % lysine remaining for glycosylated samples is determined by  
 
 
% lysine remaining = 100 – ((% Corrected lysineSPI or SPH – % Corrected lysineglycosylated )/ 
(% Corrected lysineSPI or SPH)) * 100 
          = 100 – (5.91 – 5.54) / (5.91) * 100 
                                 
                                = 93.67 % 
 
% lysine blockage got glycosylated samples is determined by  
 
% lysine blockage = 100 - % lysine remaining  
 
                              = 100 – 93.67 % 
 
                              = 6.33% 
y = 0.001x + 0.2119
R² = 0.9797
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Appendix H: Brown Pigment Development Measured at 420 nm for Partially 
Glycosylated Soy Protein (PGSP) and Partially Glycosylated Soy Protein Hydrolysate 
(PGSPH) 
 
 
 
 
Figure 5.8. Extent of Browning as determined by DUV at 420nm of A) partially glycosylated 
soy protein (PGSP):  and soy protein isolate (SPI) control;  B) partially glycosylated soy 
protein hydrolysate (PGSPH): and soy protein hydrolysate control (SPH):☐ incubated at 60°C 
for 0-120h at 0.49 aw. Error bars represent standard errors. Different lower case letters above the 
shapes indicate significant differences between different time points for the glycosylated samples 
according to Tukey-Kramer multiple means comparison test (P ≤ 0.05); n=3. 
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Appendix I: Analysis of Variance to Assess the Progression of the Mailard reaction and 
Immunoreactivity of the Modified Protein  
 
Table 5.14. Analysis of Variance for Progression of Maillard reaction of PGSP and 
PSPH 
Sample 
Analysis 
Source of 
Variation 
Degree of 
Freedom 
Mean Squares Significance 
Amadori SPI Time 5 0.015 <0.0001 
 Error 12 0.001  
Amadori SPH Time 5 0.011 <0.0001 
 Error 12 0.001  
Browning SPI Time  5 0.0000 0.003 
 Error 12 0.000002497  
Browning SPH Time 5 0.0000 0.003 
 Error 12 0.00002497  
Amine 
Blockage-SPI 
Time 5 35.246 0.019 
 Error 12 8.296  
Amine 
Blockage-SPH 
Time 5 17.256 0.791 
 Error 12 36.636  
Fluorescence-
SPI 
Time 5 0.551 0.001 
 Error 6 0.022  
Fluorescence-
SPH 
Time  5 0.706 <0.0001 
 Error 6 0.004  
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Table 5.15. Analysis of Variance to determine extent of immunoreactivity of modified 
protein 
Sample Analysis Source of 
Variation 
Degree of 
Freedom 
Mean Squares Significance 
% reduction 12 Sample 8 1950 <0.0001 
 Error 17 23.20  
% reduction 7 Sample 8 4698 <0.0001 
 Error 18 58.36  
% reduction 6 Sample  8 1317 <0.0001 
 Error  18 62.46  
% reduction 3 Sample  8 1326 <0.0001 
 Error  17 12.18  
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Appendix J: Immunoreactivity of PGSP and PGPH relative to SPI 
 
 
 
 
 
 
 
Figure 5.9: % Reduction in immunoreactivity of SPH, PGPSH, and PGSP relative to SPI 
using sera from patient 3 and 6. Error bars represent the standard errors.  
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